U.S. patent application number 14/826775 was filed with the patent office on 2016-11-17 for radioligands for pretargeted pet imaging and methods of their therapeutic use.
The applicant listed for this patent is Memorial Sloan Kettering Cancer Center. Invention is credited to Jacob Lee Houghton, Jason Lewis, Jan-Philip Meyer, Thomas Reiner, Brian Zeglis.
Application Number | 20160331852 14/826775 |
Document ID | / |
Family ID | 56413833 |
Filed Date | 2016-11-17 |
United States Patent
Application |
20160331852 |
Kind Code |
A1 |
Zeglis; Brian ; et
al. |
November 17, 2016 |
RADIOLIGANDS FOR PRETARGETED PET IMAGING AND METHODS OF THEIR
THERAPEUTIC USE
Abstract
Described herein are Tz/TCO-based pretargeting strategies using
an Al[.sup.18F]-NOTA-labeled tetrazine radioligand. This imaging
strategy enables delineation of cancer at earlier time points
compared to other imaging strategies and further decreases the
radiation dose to healthy tissues compared to directly labeled
antibodies. Al-based .sup.18F imaging of small molecules, such as
tetrazine, has not been previously achieved due to the
decomposition of tetrazine during radiofluorination.
Radiofluorination is advantageous over other radiolabeling methods
because, in addition to having a shorter half-life, .sup.18F is
more readily available to produce and therefore integrated into
hospital workflows.
Inventors: |
Zeglis; Brian; (New York,
NY) ; Lewis; Jason; (New York, NY) ; Reiner;
Thomas; (New York, NY) ; Houghton; Jacob Lee;
(New York, NY) ; Meyer; Jan-Philip; (New York,
NY) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Memorial Sloan Kettering Cancer Center |
New York |
NY |
US |
|
|
Family ID: |
56413833 |
Appl. No.: |
14/826775 |
Filed: |
August 14, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62159763 |
May 11, 2015 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 51/0482 20130101;
A61K 47/6897 20170801; A61K 51/0453 20130101 |
International
Class: |
A61K 51/04 20060101
A61K051/04 |
Goverment Interests
GOVERNMENT SUPPORT
[0002] This invention was made with government support under grant
1K99 CA178205-01 awarded by the National Institutes of Health
(NIH)/National Cancer Institute (NCI) and grants P30 CA08748, K25
EB016673, TR; R00 CA1440138, BMZ; 2R42CA128362, awarded by the
National Institutes of Health (NIH). The government has certain
rights in the invention.
Claims
[0205] 1. A composition comprising: a tetrazine moiety (Tz); a
radiolabel; a chelator; a linker attaching the tetrazine moiety
(Tz) to the chelator; and aluminum or aluminum-containing
moiety.
2. The composition of claim 1, wherein the linker is polyethylene
glycol (PEG) or (poly)-L-lysine and has a length of from 1 to 100
units and 1 to 200 units, respectively.
3. The composition of claim 1, the composition comprising:
##STR00017##
4. A radioimmunoconjugate comprising: (1) a targeting
moiety-transcyclooctene (TCO) conjugate; and (2) a radioligand
comprising a tetrazine moiety (Tz); a radiolabel; a chelator; a
linker attaching the tetrazine moiety (Tz) to the chelator; and
aluminum or aluminum-containing moiety.
5. The composition of claim 1, wherein the tetrazine moiety (Tz),
the chelator, and the linker attaching the tetrazine moiety to the
chelator comprises a member selected from the group consisting of:
2,2',2''-(3-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-1-oxo-5,8,11,14,17-
,20,23-heptaoxa-2-azapentacosan-25-yl)thioureido)benzyl)-1,4,7-triazonane--
2,5,8-triyl)triacetic acid;
2,2',2''-(3-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-1-oxo-5,8,11,14,17-
,20,23,26,29,32,35-undecaoxa-2-azaheptatriacontan-37-yl)thioureido)benzyl)-
-1,4,7-triazonane-2,5,8-triyl)triacetic acid;
2,2'-(7-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-1-oxo-5,8,11,14,17,20,-
23,26,29,32,35-undecaoxa-2-azaheptatriacontan-37-yl)thioureido)benzyl)-1,4-
,7-triazonane-1,4-diyl)diacetic acid;
2,2',2''-(3-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-3,7-dioxo-11,14,17-
,20,23,26,29-heptaoxa-2,8-diazahentriacontan-31-yl)thioureido)benzyl)-1,4,-
7-triazonane-2,5,8-triyl)triacetic acid;
2,2',2''-(3-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-3,7-dioxo-11,14,17-
,20,23,26,29,32,35,38,41-undecaoxa-2,8-diazatritetracontan-43-yl)thioureid-
o)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic acid;
2,2',2''-(3-(4-(3-(25,28-dioxo-28-((6-(6-(pyridin-2-yl)-1,2,4,5-tetrazin--
3-yl)pyridin-3-yl)amino)-3,6,9,12,15,18,21-heptaoxa-24-azaoctacosyl)thiour-
eido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic acid;
2,2',2''-(3-(4-(3-(37,40-dioxo-40-((6-(6-(pyridin-2-yl)-1,2,4,5-tetrazin--
3-yl)pyridin-3-yl)amino)-3,6,9,12,15,18,21,24,27,30,33-undecaoxa-36-azatet-
racontyl)thioureido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic
acid;
2,2',2''-(3-(4-(1-(4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenyl)-3-oxo-6,9,12-
,15,18,21,24-heptaoxa-2-azaheptacosan-27-amido)benzyl)-1,4,7-triazonane-2,-
5,8-triyl)triacetic acid;
2,2',2''-(2-(4-(1-(4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenoxy)-3,6,9,12,15-
,18,21,24,27,30,33-undecaoxahexatriacontan-36-amido)benzyl)-1,4,7-triazona-
ne-1,4,7-triyl)triacetic acid;
2,2',2''-(3-(4-(3-(5-amino-6-((4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzyl)a-
mino)-6-oxohexyl)thioureido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic
acid;
2,2'-(7-(4-(3-(5-amino-6-((4-6-methyl-1,2,4,5-tetrazin-3-yl)benzyl)-
amino)-6-oxohexyl)thioureido)benzyl)-1,4,7-triazonane-1,4-diyl)diacetic
acid;
2,2',2''-(3-(4-(3-(5-amino-6-((5-amino-6-((4-(6-methyl-1,2,4,5-tetr-
azin-3-yl)benzyl)amino)-6-oxohexyl)amino)-6-oxohexyl)thioureido)benzyl)-1,-
4,7-triazonane-2,5,8-triyl)triacetic acid; and
2,2',2''-(3-(4-(3-(5-amino-6-((5-amino-6-((5-amino-6-((4-(6-methyl-1,2,4,-
5-tetrazin-3-yl)benzyl)amino)-6-oxohexyl)amino)-6-oxohexyl)amino)-6-oxohex-
yl)thioureido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic
acid.
6. The composition of claim 1, wherein the composition is
hydrophilic.
7. The radioimmunoconjugate of claim 4, the radioligand comprising:
##STR00018##
8. The radioimmunoconjugate of claim 4, wherein the targeting
moiety-TCO conjugate has a TCO moiety comprising: ##STR00019##
9. The radioimmunoconjugate of claim 4, wherein the linker is
polyethylene glycol (PEG) or (poly)-L-lysine and has a length of
from 1 to 100 units and 1 to 200 units, respectively.
10. A method for synthesizing a radioligand: (1) preparing
Tz-PEG.sub.11-NOTA (tetrazine-polyethylene
glycol-1,4,7-triazonane-1,4,7-triyl-triacetic acid); (2) preparing
a Al-.sup.18F complex; and (3) reacting the Tz-PEG.sub.11-NOTA and
the Al-.sup.18F complex to yield the radioligand
Tz-PEG.sub.11-Al[.sup.18F]-NOTA, wherein the radioligand is
obtained in 54% to 65% radiochemical yield (decay-corrected to a
start of synthesis) with a purity greater than 96% and specific
activities between 20 to 30 Gbq/.mu.mol.
11. A method for detecting tumor cells, the method comprising: (1)
administering a quantity of targeting moiety-transcyclooctene (TCO)
conjugate to a subject, wherein a portion of the targeting
moiety-TCO conjugate localizes at the tumor cells and unbound
targeting moiety-TCO conjugate is cleared from blood, from renal
system, and/or from the subject after an accumulation interval; (2)
administering a radioligand to the subject after the accumulation
interval, wherein the radioligand comprises a tetrazine moiety
(Tz); a radiolabel; a chelator; a linker attaching the tetrazine
moiety (Tz) to the chelator; and aluminum or aluminum-containing
moiety, wherein the targeting moiety-TCO conjugate and the
radioligand bind together to form a radioimmunoconjugate via an in
vivo click reaction at the tumor cells within a region of the
subject; and (3) imaging via positron emission tomography (PET)
imaging the radioimmunoconjugate accumulated in the region of the
subject within a time period less than 9 hours from the
administering of the radioligand.
12. The method of claim 11, wherein the radioligand comprises:
##STR00020##
13. The method of claim 11, wherein the targeting moiety-TCO
conjugate has a TCO moiety comprising: ##STR00021##
14. The method of claim 11, wherein the radioligand has an
effective dose of less than 0.1 rem/mCi over a 4 hour accumulation
interval.
15. The method of claim 11, wherein the radioligand has a half-life
in blood that is less than 100 minutes.
16. The method of claim 11, wherein the radioimmunoconjugate has an
activity concentration in a large intestine of the subject that is
less than 2% of an initial dose per gram (ID/g) after 2 hour post
injection.
17. The method of claim 11, wherein the radioimmunoconjugate has an
activity concentration in a gastrointestinal tract of the subject
that is less than 2% of an initial dose per gram (ID/g) after 2
hour post injection.
18. The method of claim 11, wherein the radioimmunoconjugate has an
activity concentration in a hepatobiliary system of the subject
that is less than 2% of an initial dose per gram (ID/g after 2 hour
post injection.
19. The method of claim 11, wherein the linker is polyethylene
glycol (PEG) or (poly)-L-lysine and has a length of from 1 to 100
units and 1 to 200 units, respectively.
20. The method of claim 11, wherein the radioligand is
hydrophilic.
21. The method of claim 11, wherein the targeting moiety is an
antibody.
22. The method of claim 21, wherein the antibody is a member
selected from the group consisting of trastuzumab, J591,
bevacizumab, B43.13, AR9.6, 3F8, 8H9, huA33, and 5B1.
23. The method of claim 11, wherein the targeting moiety is a
nanoparticle, a peptide, or other biomolecule.
24. The method of claim 11, wherein the tumor cells are colorectal
tumor cells or pancreatic tumor cells.
25. The method of claim 11, wherein the tetrazine moiety (Tz), the
chelator, and the linker attaching the tetrazine moiety to the
chelator comprises a member selected from the group consisting of:
2,2',2''-(3-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-1-oxo-5,8,11,14,17-
,20,23-heptaoxa-2-azapentacosan-25-yl)thioureido)benzyl)-1,4,7-triazonane--
2,5,8-triyl)triacetic acid;
2,2',2''-(3-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-1-oxo-5,8,11,14,17-
,20,23,26,29,32,35-undecaoxa-2-azaheptatriacontan-37-yl)thioureido)benzyl)-
-1,4,7-triazonane-2,5,8-triyl)triacetic acid;
2,2'-(7-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-1-oxo-5,8,11,14,17,20,-
23,26,29,32,35-undecaoxa-2-azaheptatriacontan-37-yl)thioureido)benzyl)-1,4-
,7-triazonane-1,4-diyl)diacetic acid;
2,2',2''-(3-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-3,7-dioxo-11,14,17-
,20,23,26,29-heptaoxa-2,8-diazahentriacontan-31-yl)thioureido)benzyl)-1,4,-
7-triazonane-2,5,8-triyl)triacetic acid;
2,2',2''-(3-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-3,7-dioxo-11,14,17-
,20,23,26,29,32,35,38,41-undecaoxa-2,8-diazatritetracontan-43-yl)thioureid-
o)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic acid;
2,2',2''-(3-(4-(3-(25,28-dioxo-28-((6-(6-(pyridin-2-yl)-1,2,4,5-tetrazin--
3-yl)pyridin-3-yl)amino)-3,6,9,12,15,18,21-heptaoxa-24-azaoctacosyl)thiour-
eido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic acid;
2,2',2''-(3-(4-(3-(37,40-dioxo-40-((6-(6-(pyridin-2-yl)-1,2,4,5-tetrazin--
3-yl)pyridin-3-yl)amino)-3,6,9,12,15,18,21,24,27,30,33-undecaoxa-36-azatet-
racontyl)thioureido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic
acid;
2,2',2''-(3-(4-(1-(4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenyl)-3-oxo-6,9,12-
,15,18,21,24-heptaoxa-2-azaheptacosan-27-amido)benzyl)-1,4,7-triazonane-2,-
5,8-triyl)triacetic acid;
2,2',2''-(2-(4-(1-(4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenoxy)-3,6,9,12,15-
,18,21,24,27,30,33-undecaoxahexatriacontan-36-amido)benzyl)-1,4,7-triazona-
ne-1,4,7-triyl)triacetic acid;
2,2',2''-(3-(4-(3-(5-amino-6-((4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzyl)a-
mino)-6-oxohexyl)thioureido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic
acid;
2,2'-(7-(4-(3-(5-amino-6-((4-6-methyl-1,2,4,5-tetrazin-3-yl)benzyl)-
amino)-6-oxohexyl)thioureido)benzyl)-1,4,7-triazonane-1,4-diyl)diacetic
acid;
2,2',2''-(3-(4-(3-(5-amino-6-((5-amino-6-((4-(6-methyl-1,2,4,5-tetr-
azin-3-yl)benzyl)amino)-6-oxohexyl)amino)-6-oxohexyl)thioureido)benzyl)-1,-
4,7-triazonane-2,5,8-triyl)triacetic acid; and
2,2',2''-(3-(4-(3-(5-amino-6-((5-amino-6-((5-amino-6-((4-(6-methyl-1,2,4,-
5-tetrazin-3-yl)benzyl)amino)-6-oxohexyl)amino)-6-oxohexyl)amino)-6-oxohex-
yl)thioureido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic
acid.
26-45. (canceled)
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to and the benefit of, and
incorporates herein by reference in its entirety, U.S. Provisional
Patent Application No. 62/159,763, filed May 11, 2015.
FIELD OF THE INVENTION
[0003] This invention relates generally to pretargeted positron
emission tomography (PET) imaging of cancer. In particular
embodiments, the invention relates to radioligands for pretargeted
PET imaging of cancer (e.g., colorectal, pancreatic, etc.).
BACKGROUND
[0004] Over the past 25 years, antibodies have emerged as effective
vectors for the sensitive and specific delivery of radioisotopes to
tumors. A wide variety of radionuclides ranging from 1241 for
positron emission tomography (PET) to 225Ac for targeted
radiotherapy have been conjugated to antibodies for preclinical
investigations and clinical applications. However, the size and
dosing of these radiolabeled antibodies have obstructed clinical
utility. For example, intact IgG antibodies have relatively long
biological half-lives due to their size, which causes them to
require multiple days to weeks to reach their optimal
biodistribution. Consequently, the large size of intact IgGs
requires isotopes with long physical half-lives, such as .sup.89Zr
(t.sub.1/2=3.26 d) or .sup.24I (t.sub.1/2=4.2 d) for PET or
.sup.177Lu (t.sub.1/2=6.73 d) for radiotherapy. While the resulting
radioimmunoconjugates can deliver high concentrations of activity
to tumor tissue, the long circulation times and radioactive
half-lives combine to produce significant and potentially
deleterious radiation doses to healthy tissues.
[0005] To overcome these limitations, radiopharmaceuticals based on
truncated immunoglobulins, such as F(ab')2, F(ab'), and scFv
fragments have been developed to provide imaging agents that
combine the specificity and affinity of intact IgGs with the rapid
pharmacokinetics and favorable dosimetry of smaller molecules.
However, preclinical studies have shown that the smaller size and
more rapid pharmacokinetics result in decreased activity
concentrations in the targeted tissue in addition to increased
activity concentrations in excretory organs such as the
kidneys.
[0006] To address these limitations, pretargeting, or strategies to
decouple the antibody from the radioactivity at the time of
injection, have been developed to provide an alternative approach
to harness the high affinity and specificity of intact IgGs, while
avoiding their pharmacokinetic drawbacks. Pretargeting uses an
antibody designed to bind both a target antigen and a radiolabeled
hapten. The antibody is injected into the blood and, in turn, is
given time to accumulate at the tumor and concomitantly clear from
the body. After the accumulation, a radiolabeled hapten is
administered intravenously. The radioligand either binds to the
antibody at the tumor or, due to its small size, rapidly clears
from the body. If the radioligand binds to the antibody, the final
radioimmunconjugate is formed at the tumor site. Thus, pretargeting
achieves delineation of tumor tissue at much earlier time points
than traditional radioimmunoconjugates while significantly reducing
the overall radiation burden to the patient.
[0007] Until recently, three types of pretargeting technologies
have been used: (1) streptavidin-fused antibodies and biotin-based
radioligands, (2) oligonucleotide-labeled antibodies and
radioligands bearing complementary sequences, and (3) bispecific
antibodies that bind both a target antigen and a radiolabeled
hapten (e.g., .sup.90Y-DOTA). Yet despite significant preclinical
successes, the widespread application of each strategy has been
hampered by its intrinsic limitations. For example, the
immunogenicity of the streptavidin-bearing immunoconjugates or the
inherent lack of modularity of bispecific antibodies limits use in
clinics.
[0008] Over the last few years, a pretargeting strategy based on
the inverse electron demand Diels-Alder (IEDDA) reaction between
tetrazine (Tz) and transcyclooctene (TCO) was developed and is
depicted in FIG. 1. The IEDDA cycloaddition as a click chemistry
conjugation reaction has been used for a variety of applications,
including the fluorescent labeling of nanoparticles, antibodies,
oligonucleotides, and small molecules, as well as the traditional
synthesis of radiopharmaceuticals.
[0009] The IEDDA reaction was thought to be a promising tool for in
vivo pretargeting. For example, the IEDDA reaction is
extraordinarily rapid (k.sub.1 greater than 30,000 M.sup.-1
s.sup.-1), selective, robust, and bioorthogonal. The use of IEDDA
in pretargeting was pioneered largely by Rossin, et al., who
published an .sup.111In-based SPECT imaging approach and have
improved their systems to use tetrazine-bearing clearing agents and
more reactive dienophiles (Rossin, R.; van den Bosch, S. M.; Ten
Hoeve, W.; Carvelli, M.; Versteegen, R. M.; Lub, J.; Robillard, M.
S., Highly reactive trans-cyclooctene tags with improved stability
for Diels-Alder chemistry in living systems. Bioconj. Chem. 2014,
34, 1210-1217).
[0010] An alternative pretargeting PET imaging strategy based on
the IEDDA reaction was reported by Zeglis, B. M. et al. Journal of
Nuclear Medicine. 54, 1389-1396 (2013) and in U.S. Provisional
Application No. 62/159,763, which are hereby incorporated by
reference herein in their entireties. This strategy featured a
rapid and selective in vivo biorthogonal reaction between
trans-cyclooctene (TCO) and tetrazine (Tz). The use of antibodies
labeled with TCO and small molecule tetrazine-based radioligands
allowed radioactive labeling of antibodies after accumulation at
the target site in vivo. However, one of the drawbacks of this
system was that the .sup.64Cu-NOTA-labeled tetrazine radioligand
cleared too slowly from the gut (e.g., small intestine, large
intestine, etc.). Although the pretargeting system delineated
cancer tumors with this radioligand, later imaging time points
(e.g., at 12 hours (h)) were required to achieve high image
contrast, and the dosimetric benefits of the system were not
significant. Moreover, unclicked .sup.64Cu-Tz-NOTA radioligand was
cleared sluggishly through the intestines, hindering use as a
clinical imaging system for cancer (e.g., colorectal) detection.
The U.S. Provisional Application No. 62/159,763 reports a
.sup.64Cu-labeled radioligand employed for the pretargeted PET
imaging of SW1222 human colorectal cancer xenografts.
[0011] As the half-life of .sup.64Cu is 12.74 hours the potential
of utilizing even shorter-lived radionuclides to decrease the time
period between the administration of the radiotracer and imaging
(e.g., generate an image at an earlier time point) has significant
clinical benefits: The ability to acquire clinical imaging data at
earlier time points reduces radiation exposure to the patient and
expedites the time that the patient is in the hospital.
[0012] As mentioned above, various pretargeting strategies based on
the IEDDA reaction between Tz and TCO have been developed using
.sup.64Cu-based approaches. In addition to the aforementioned
advantages of short-lived radionuclides, the availability of
.sup.18F (or .sup.68Ga) is considerably higher compared to
.sup.64Cu for instance as most hospitals and imaging centers do not
produce .sup.64Cu locally and rely on the delivery from external
sources. In contrast to .sup.64Cu, most hospitals and imaging
centers have the ability to produce the .sup.18F radionuclide in
house and hence make the use of .sup.18F-labeled radiotracer
logistically more desirable.
[0013] Although .sup.18F-incorporation into the Tz moiety has been
attempted (Li, Z, et al., Chem. Commun., 2010, 46, 8043-8045, Li,
Z, et al., Chem. Commun., 2010, 46, 8043-8045, Reiner and Zeglis,
J. Label Compd. Radiopharm, 2013), this has not been successful,
and workarounds have been necessary, for example, attaching the
.sup.18F radionuclide to TCO or dextran. The radiosynthesis of
.sup.18F attached to a small molecule, such as an .sup.18F-labeled
tetrazine moiety capable of pretargeted in vivo imaging, has not
been published.
[0014] Therefore, there is a need to develop low-dose
radioimmunoconjugates that delineate cancer from healthy tissue in
small amounts of time, possess favorable pharmacokinetic profiles,
can be cleared rapidly from the body to enable high contrast PET
imaging of cancer (e.g., colorectal, pancreatic), and are
commercially available to or synthesized by hospitals.
SUMMARY OF INVENTION
[0015] Described herein are Tz/TCO-based pretargeting strategies
using (1) a .sup.64Cu-sarcophagine-based tetrazine radioligand for
pretargeted PET imaging with more rapid excretion of the excess
radioligand through the bladder and kidneys and (2) an
Al[.sup.18F]-NOTA-labeled tetrazine radioligand. These imaging
strategies enable delineation of cancer at earlier time points
compared to other imaging strategies and further decrease the
radiation dose to healthy tissues compared to directly labeled
antibodies.
[0016] The present disclosure describes the development and in vivo
validation of an improved strategy for pretargeted PET imaging of
colorectal and pancreatic cancer.
[0017] In certain embodiments, the present disclosure describes the
synthesis and characterization of in vivo behavior of two
.sup.64Cu-labeled tetrazine radioligands:
.sup.64Cu-Tz-PEG.sub.7-NOTA and .sup.64Cu-Tz-SarAr. These two
radioligands possess structural alterations that modulate their
pharmacokinetic profile compared to prior imaging systems. In some
example embodiments, the system described herein produces higher
activity concentrations in the tumor and, due to the renal
excretion of the unbound radioligand disclosed herein, provides
improved tumor-to-background activity concentration ratios at early
time points. Furthermore, the presently disclosed methodologies
function at significantly lower dose rates required by directly
labeled radioimmunoconjugates. In some certain embodiments, the
present imaging strategies can be effective for any cancer (e.g.,
colorectal, pancreatic) for which a non-internalizing,
biomarker-targeted antibody exists.
[0018] In certain embodiments, a TCO-bearing immuno-conjugate of
the anti-CA19.9 antibody 5B1 and an Al[.sup.18F]-NOTA-labeled
tetrazine radioligand were harnessed for the visualization of
CA19.9-expressing BxPC3 pancreatic cancer xenografts. Al-based
.sup.18F imaging of small molecules, such as tetrazine, has not
been previously achieved due to the decomposition of tetrazine
during radiofluorination. Radiofluorination is advantageous over
other radiolabeling methods because, in addition to having a
shorter half-life, .sup.18F is more readily available to produce,
and therefore, more suited to be integrated into hospital
workflows. Biodistribution and .sup.18F-PET imaging data clearly
demonstrate that this methodology effectively delineates tumor mass
with activity concentrations up to 6.4% ID/g at 4 h after injection
of the radioligand.
[0019] In one aspect, the invention is directed to a composition
comprising: a tetrazine moiety (Tz); a radiolabel (e.g., 18F); a
chelator (e.g., 1,4,7-triazonane-1,4,7-triyl-triacetic acid (NOTA),
e.g., 1,4,7-triazacyclononane-1,4-diacetate (NODA)); a linker
(e.g., polyethylene glycol, (poly)-L-lysine) attaching the
tetrazine moiety (Tz) to the chelator; and aluminum or
aluminum-containing moiety (e.g., wherein the radiolabel is
attached to aluminum).
[0020] In certain embodiments, the linker is polyethylene glycol
(PEG) or (poly)-L-lysine and has a length of from 1 to 100 units
and 1 to 200 units, respectively.
[0021] In certain embodiments, the composition comprises:
##STR00001##
[0022] In another aspect, the invention is directed to a
radioimmunoconjugate comprising: (1) a targeting
moiety-transcyclooctene (TCO) conjugate (e.g., TCO-5B1); and (2) a
radioligand (e.g., attached to the targeting moiety-TCO conjugate)
comprising a tetrazine moiety (Tz); a radiolabel (e.g., 18F); a
chelator (e.g., 1,4,7-triazonane-1,4,7-triyl-triacetic acid (NOTA),
e.g., 1,4,7-triazacyclononane-1,4-diacetate (NODA)); a linker
(e.g., polyethylene glycol, (poly)-L-lysine) attaching the
tetrazine moiety (Tz) to the chelator; and aluminum or
aluminum-containing moiety (e.g., wherein the radiolabel is
attached to aluminum).
[0023] In certain embodiments, the tetrazine moiety (Tz), the
chelator, and the linker attaching the tetrazine moiety to the
chelator comprises a member selected from the group consisting of:
2,2',2''-(3-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-1-oxo-5,8,11,14,17-
,20,23-heptaoxa-2-azapentacosan-25-yl)thioureido)benzyl)-1,4,7-triazonane--
2,5,8-triyl)triacetic acid;
2,2',2''-(3-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-1-oxo-5,8,11,14,17-
,20,23,26,29,32,35-undecaoxa-2-azaheptatriacontan-37-yl)thioureido)benzyl)-
-1,4,7-triazonane-2,5,8-triyl)triacetic acid;
2,2'-(7-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-1-oxo-5,8,11,14,17,20,-
23,26,29,32,35-undecaoxa-2-azaheptatriacontan-37-yl)thioureido)benzyl)-1,4-
,7-triazonane-1,4-diyl)diacetic acid;
2,2',2''-(3-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-3,7-dioxo-11,14,17-
,20,23,26,29-heptaoxa-2,8-diazahentriacontan-31-yl)thioureido)benzyl)-1,4,-
7-triazonane-2,5,8-triyl)triacetic acid;
2,2',2''-(3-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-3,7-dioxo-11,14,17-
,20,23,26,29,32,35,38,41-undecaoxa-2,8-diazatritetracontan-43-yl)thioureid-
o)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic acid;
2,2',2''-(3-(4-(3-(25,28-dioxo-28-((6-(6-(pyridin-2-yl)-1,2,4,5-tetrazin--
3-yl)pyridin-3-yl)amino)-3,6,9,12,15,18,21-heptaoxa-24-azaoctacosyl)thiour-
eido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic acid;
2,2',2''-(3-(4-(3-(37,40-dioxo-40-((6-(6-(pyridin-2-yl)-1,2,4,5-tetrazin--
3-yl)pyridin-3-yl)amino)-3,6,9,12,15,18,21,24,27,30,33-undecaoxa-36-azatet-
racontyl)thioureido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic
acid;
2,2',2''-(3-(4-(1-(4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenyl)-3-oxo-6,9,12-
,15,18,21,24-heptaoxa-2-azaheptacosan-27-amido)benzyl)-1,4,7-triazonane-2,-
5,8-triyl)triacetic acid;
2,2',2''-(2-(4-(1-(4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenoxy)-3,6,9,12,15-
,18,21,24,27,30,33-undecaoxahexatriacontan-36-amido)benzyl)-1,4,7-triazona-
ne-1,4,7-triyl)triacetic acid;
2,2',2''-(3-(4-(3-(5-amino-6-((4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzyl)a-
mino)-6-oxohexyl)thioureido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic
acid;
2,2'-(7-(4-(3-(5-amino-6-((4-6-methyl-1,2,4,5-tetrazin-3-yl)benzyl)-
amino)-6-oxohexyl)thioureido)benzyl)-1,4,7-triazonane-1,4-diyl)diacetic
acid;
2,2',2''-(3-(4-(3-(5-amino-6-((5-amino-6-((4-(6-methyl-1,2,4,5-tetr-
azin-3-yl)benzyl)amino)-6-oxohexyl)amino)-6-oxohexyl)thioureido)benzyl)-1,-
4,7-triazonane-2,5,8-triyl)triacetic acid; and
2,2',2''-(3-(4-(3-(5-amino-6-((5-amino-6-((5-amino-6-((4-(6-methyl-1,2,4,-
5-tetrazin-3-yl)benzyl)amino)-6-oxohexyl)amino)-6-oxohexyl)amino)-6-oxohex-
yl)thioureido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic
acid.
[0024] In certain embodiments, the composition is hydrophilic
(e.g., having a partition coefficient less than 2).
[0025] In certain embodiments, the radioligand comprises:
##STR00002##
[0026] In certain embodiments, the targeting moiety-TCO conjugate
has a TCO moiety comprises:
##STR00003##
[0027] In certain embodiments, wherein linker is polyethylene
glycol (PEG) or (poly)-L-lysine and has a length of from 1 to 100
units and 1 to 200 units, respectively.
[0028] In another aspect, the invention is directed to a method for
synthesizing a radioligand: (1) preparing Tz-PEG11-NOTA
(tetrazine-polyethylene
glycol-1,4,7-triazonane-1,4,7-triyl-triacetic acid) (e.g.,
comprising coupling Tz-NHS (tetrazine-N-hydroxysuccinimide) to
NH2-PEG11-NHBoc; deprotecting the terminal tert-butyloxycarbonyl
protecting group to obtain Tz-PEG11-NH2; and reacting Tz-PEG11-NH2
with p-SCN-Bn-NOTA to yield Tz-PEG11-NOTA (e.g., wherein
Tz-PEG11-NOTA is prepared with a purity of greater than 98% and
with an overall yield of greater than 10%)); (2) preparing a
Al-.sup.18F complex (e.g., comprising eluting [18F]fluoride into a
metal-free solvent; mixing the eluted [18F]fluoride with a
AlCl3-solution (e.g., wherein mixing is performed at room
temperature and a pH of 3.5-4); incubating the mixture (e.g.,
wherein the mixture is incubated at 30.degree. C.); and (3)
reacting the Tz-PEG11-NOTA (e.g., wherein the solvent of the
prepared Tz-PEG11-NOTA is acetonitrile (MeCN)/water in a volumetric
ratio of 3:1) and the Al-.sup.18F complex to yield the radioligand
Tz-PEG11-Al[.sup.18F]-NOTA, wherein the radioligand is obtained in
54% to 65% radiochemical yield (decay-corrected to the start of
synthesis) with a purity greater than 96% and specific activities
between 20 to 30 Gbq/.mu.mol.
[0029] In another aspect, the invention is directed to a method for
detecting tumor cells, the method comprising: (1) administering
(e.g., injecting) a quantity of targeting moiety-transcyclooctene
(TCO) conjugate (e.g., TCO-5B1) to a subject, wherein a portion of
the targeting moiety-TCO conjugate localizes at the tumor cells and
unbound targeting moiety-TCO conjugate is cleared (e.g., from the
blood, from the renal system, and/or from the subject) after an
accumulation interval (e.g., wherein the accumulation interval is
less than 240 hours, e.g., less than 216 hours, e.g., less than 192
hours, e.g., less than 144 hours, e.g., less than 120 hours, e.g.,
less than 96 hours, e.g., less than 72 hours, e.g., less than 48
hours, e.g., less than 24 hours); (2) administering (e.g.,
injecting) a radioligand to the subject after the accumulation
interval, wherein the radioligand comprises a tetrazine moiety
(Tz); a radiolabel (e.g., 18F); a chelator (e.g.,
1,4,7-triazonane-1,4,7-triyl-triacetic acid (NOTA), e.g.,
1,4,7-triazacyclononane-1,4-diacetate (NODA)); a linker (e.g.,
polyethylene glycol, (poly)-L-lysine) attaching the tetrazine
moiety (Tz) to the chelator; and aluminum or aluminum-containing
moiety (e.g., wherein the radiolabel is attached to aluminum),
wherein the targeting moiety-TCO conjugate and the radioligand bind
together to form a radioimmunoconjugate via an in vivo click
reaction at the tumor site within a region of the subject; and (3)
imaging (e.g., via positron emission tomography (PET) imaging) the
radioimmunoconjugate accumulated in the region of the subject
within a time period less than 9 hours (e.g., less than 6 hours,
less than 4 hours, less than 2 hours) from the administering of the
radioligand.
[0030] In certain embodiments, the radioligand comprises:
##STR00004##
[0031] In certain embodiments, the targeting moiety-TCO conjugate
has a TCO moiety comprising:
##STR00005##
[0032] In certain embodiments, the radioligand has an effective
dose of less than 0.1 rem/mCi (e.g., less than 0.05 rem/mCi) over a
4 hour accumulation interval.
[0033] In certain embodiments, the radioligand has a half-life in
blood that is less than 100 minutes.
[0034] In certain embodiments, the radioimmunoconjugate has an
activity concentration in a large intestine of the subject that is
less than 2% of the initial dose per gram (ID/g) (e.g., less than
1% ID/g, e.g., less than 0.5% ID/g, e.g., less than 0.1% % ID/g)
after 2 hour post injection.
[0035] In certain embodiments, the radioimmunoconjugate has an
activity concentration in a gastrointestinal tract of the subject
that is less than 2% of the initial dose per gram (ID/g) (e.g.,
less than 1% ID/g, less than 0.5% ID/g, e.g., less than 0.1% %
ID/g) after 2 hour post injection.
[0036] In certain embodiments, the radioimmunoconjugate has an
activity concentration in a hepatobiliary system of the subject
that is less than 2% of the initial dose per gram (ID/g) (e.g.,
less than 1% ID/g, less than 0.5% ID/g, e.g., less than 0.1% %
ID/g) after 2 hour post injection.
[0037] In certain embodiments, the linker is polyethylene glycol
(PEG) or (poly)-L-lysine and has a length of from 1 to 100 units
and 1 to 200 units, respectively.
[0038] In certain embodiments, the radioligand is hydrophilic
(e.g., wherein the hydrophilicity of the composition is determined
by a partition coefficient (e.g., wherein the partition coefficient
is less than 2)).
[0039] In certain embodiments, the targeting moiety is an antibody.
In certain embodiments, the antibody is a member selected from the
group consisting of trastuzumab, J591, bevacizumab, B43.13, AR9.6,
3F8, 8H9, huA33, and 5B1. In certain embodiments, the targeting
moiety is a nanoparticle, a peptide, or other biomolecule.
[0040] In certain embodiments, the tumor cells are colorectal tumor
cells or pancreatic tumor cells (e.g., wherein the tumor cells can
be detected using a non-internalizing, biomarker-targeted antibody)
(e.g., wherein the tumor cells comprise a biomarker on the surface
of the cell).
[0041] In certain embodiments, the tetrazine moiety (Tz), the
chelator, and the linker attaching the tetrazine moiety to the
chelator comprises a member selected from the group consisting of:
2,2',2''-(3-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-1-oxo-5,8,11,14,17-
,20,23-heptaoxa-2-azapentacosan-25-yl)thioureido)benzyl)-1,4,7-triazonane--
2,5,8-triyl)triacetic acid;
2,2',2''-(3-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-1-oxo-5,8,11,14,17-
,20,23,26,29,32,35-undecaoxa-2-azaheptatriacontan-37-yl)thioureido)benzyl)-
-1,4,7-triazonane-2,5,8-triyl)triacetic acid;
2,2'-(7-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-1-oxo-5,8,11,14,17,20,-
23,26,29,32,35-undecaoxa-2-azaheptatriacontan-37-yl)thioureido)benzyl)-1,4-
,7-triazonane-1,4-diyl)diacetic acid;
2,2',2''-(3-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-3,7-dioxo-11,14,17-
,20,23,26,29-heptaoxa-2,8-diazahentriacontan-31-yl)thioureido)benzyl)-1,4,-
7-triazonane-2,5,8-triyl)triacetic acid;
2,2',2''-(3-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-3,7-dioxo-11,14,17-
,20,23,26,29,32,35,38,41-undecaoxa-2,8-diazatritetracontan-43-yl)thioureid-
o)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic acid;
2,2',2''-(3-(4-(3-(25,28-dioxo-28-((6-(6-(pyridin-2-yl)-1,2,4,5-tetrazin--
3-yl)pyridin-3-yl)amino)-3,6,9,12,15,18,21-heptaoxa-24-azaoctacosyl)thiour-
eido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic acid;
2,2',2''-(3-(4-(3-(37,40-dioxo-40-((6-(6-(pyridin-2-yl)-1,2,4,5-tetrazin--
3-yl)pyridin-3-yl)amino)-3,6,9,12,15,18,21,24,27,30,33-undecaoxa-36-azatet-
racontyl)thioureido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic
acid;
2,2',2''-(3-(4-(1-(4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenyl)-3-oxo-6,9,12-
,15,18,21,24-heptaoxa-2-azaheptacosan-27-amido)benzyl)-1,4,7-triazonane-2,-
5,8-triyl)triacetic acid;
2,2',2''-(2-(4-(1-(4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenoxy)-3,6,9,12,15-
,18,21,24,27,30,33-undecaoxahexatriacontan-36-amido)benzyl)-1,4,7-triazona-
ne-1,4,7-triyl)triacetic acid;
2,2',2''-(3-(4-(3-(5-amino-6-((4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzyl)a-
mino)-6-oxohexyl)thioureido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic
acid;
2,2'-(7-(4-(3-(5-amino-6-((4-6-methyl-1,2,4,5-tetrazin-3-yl)benzyl)-
amino)-6-oxohexyl)thioureido)benzyl)-1,4,7-triazonane-1,4-diyl)diacetic
acid;
2,2',2''-(3-(4-(3-(5-amino-6-((5-amino-6-((4-(6-methyl-1,2,4,5-tetr-
azin-3-yl)benzyl)amino)-6-oxohexyl)amino)-6-oxohexyl)thioureido)benzyl)-1,-
4,7-triazonane-2,5,8-triyl)triacetic acid; and
2,2',2''-(3-(4-(3-(5-amino-6-((5-amino-6-((5-amino-6-((4-(6-methyl-1,2,4,-
5-tetrazin-3-yl)benzyl)amino)-6-oxohexyl)amino)-6-oxohexyl)amino)-6-oxohex-
yl)thioureido)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic
acid.
[0042] In another aspect, the invention is directed to a kit for
targeted positron emission tomography (PET) comprising: a plurality
of containers, wherein each container has a type selected from an
ampule, a vial, a cartridge, a reservoir, a lyo-ject, or a
pre-filled syringe; the composition; and a targeting
moiety-transcyclooctene (TCO) conjugate (e.g., TCO-5B1), wherein a
first container of the plurality of containers holds (e.g.,
contains) the composition (e.g., a first solution comprising the
composition); and a second container of the plurality of containers
holds (e.g., contains) the targeting moiety-TCO conjugate (e.g., a
second solution comprising the conjugate).
DEFINITIONS
[0043] In order for the present disclosure to be more readily
understood, certain terms are first defined below. Additional
definitions for the following terms and other terms are set forth
throughout the specification.
[0044] In this application, the use of "or" means "and/or" unless
stated otherwise. As used in this application, the term "comprise"
and variations of the term, such as "comprising" and "comprises,"
are not intended to exclude other additives, components, integers
or steps. As used in this application, the terms "about" and
"approximately" are used as equivalents. Any numerals used in this
application with or without about/approximately are meant to cover
any normal fluctuations appreciated by one of ordinary skill in the
relevant art. In certain embodiments, the term "approximately" or
"about" refers to a range of values that fall within 25%, 20%, 19%,
18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%,
4%, 3%, 2%, 1%, or less in either direction (greater than or less
than) of the stated reference value unless otherwise stated or
otherwise evident from the context (except where such number would
exceed 100% of a possible value).
[0045] "Administration": The term "administration" refers to
introducing a substance into a subject. In general, any route of
administration may be utilized including, for example, parenteral
(e.g., intravenous), oral, topical, subcutaneous, peritoneal,
intraarterial, inhalation, vaginal, rectal, nasal, introduction
into the cerebrospinal fluid, or instillation into body
compartments. In some embodiments, administration is oral.
Additionally or alternatively, in some embodiments, administration
is parenteral. In some embodiments, administration is
intravenous.
[0046] "Biocompatible": The term "biocompatible", as used herein is
intended to describe materials that do not elicit a substantial
detrimental response in vivo. In certain embodiments, the materials
are "biocompatible" if they are not toxic to cells. In certain
embodiments, materials are "biocompatible" if their addition to
cells in vitro results in less than or equal to 20% cell death,
and/or their administration in vivo does not induce inflammation or
other such adverse effects. In certain embodiments, materials are
biodegradable.
[0047] "Biodegradable": As used herein, "biodegradable" materials
are those that, when introduced into cells, are broken down by
cellular machinery (e.g., enzymatic degradation) or by hydrolysis
into components that cells can either reuse or dispose of without
significant toxic effects on the cells. In certain embodiments,
components generated by breakdown of a biodegradable material do
not induce inflammation and/or other adverse effects in vivo. In
some embodiments, biodegradable materials are enzymatically broken
down. Alternatively or additionally, in some embodiments,
biodegradable materials are broken down by hydrolysis. In some
embodiments, biodegradable polymeric materials break down into
their component polymers. In some embodiments, breakdown of
biodegradable materials (including, for example, biodegradable
polymeric materials) includes hydrolysis of ester bonds. In some
embodiments, breakdown of materials (including, for example,
biodegradable polymeric materials) includes cleavage of urethane
linkages.
[0048] "Biomolecule": As used herein, "biomolecule" refers to
bioactive, diagnostic, and prophylactic molecules. Biomolecules
that can be used in the present invention include, but are not
limited to, synthetic, recombinant or isolated peptides and
proteins such as antibodies and antigens, receptor ligands,
enzymes, and adhesion peptides; nucleotides and polynucleic acids
such as DNA and antisense nucleic acid molecule; activated sugars
and polysaccharides; bacteria; viruses; and chemical drugs such as
antibiotics, antiinflammatories, and antifungal agents.
[0049] "Carrier": As used herein, "carrier" refers to a diluent,
adjuvant, excipient, or vehicle with which the compound is
administered. Such pharmaceutical carriers can be sterile liquids,
such as water and oils, including those of petroleum, animal,
vegetable or synthetic origin, such as peanut oil, soybean oil,
mineral oil, sesame oil and the like. Water or aqueous solution
saline solutions and aqueous dextrose and glycerol solutions are
preferably employed as carriers, particularly for injectable
solutions. Suitable pharmaceutical carriers are described in
"Remington's Pharmaceutical Sciences" by E. W. Martin.
[0050] "Radiolabel": As used herein, "radiolabel" refers to a
moiety comprising a radioactive isotope of at least one element.
Exemplary suitable radiolabels include but are not limited to those
described herein. In some embodiments, a radiolabel is one used in
positron emission tomography (PET). In some embodiments, a
radiolabel is one used in single-photon emission computed
tomography (SPECT). In some embodiments, radioisotopes comprise
.sup.99mTc, .sup.111In, .sup.64Cu, .sup.67Ga, .sup.186Re,
.sup.188Re, .sup.153Sm, .sup.177Lu, .sup.67Cu, .sup.123I,
.sup.124I, .sup.125I, .sup.11C, .sup.13N, .sup.15O, .sup.18F,
.sup.186Re, .sup.188Re, .sup.153Sm, .sup.166Ho, .sup.177Lu,
.sup.149Pm, .sup.90Y, .sup.213Bi, .sup.103Pd, .sup.109Pd,
.sup.159Gd, .sup.140La, .sup.198Au, .sup.199Au, .sup.169Yb,
.sup.175Yb, .sup.165Dy, .sup.166Dy, .sup.67Cu, .sup.105Rh,
.sup.111Ag, .sup.89Zr, .sup.225Ac, and .sup.192Ir.
[0051] "Subject": As used herein, the term "subject" includes
humans and mammals (e.g., mice, rats, pigs, cats, dogs, and
horses). In many embodiments, subjects are be mammals, particularly
primates, especially humans. In some embodiments, subjects are
livestock such as cattle, sheep, goats, cows, swine, and the like;
poultry such as chickens, ducks, geese, turkeys, and the like; and
domesticated animals particularly pets such as dogs and cats. In
some embodiments (e.g., particularly in research contexts) subject
mammals will be, for example, rodents (e.g., mice, rats, hamsters),
rabbits, primates, or swine such as inbred pigs and the like.
[0052] "Small molecule": As used herein, the term "small molecule"
can refer to a non-polymeric molecule, for example, or a species
less than 5000 Da.
[0053] "Therapeutic agent": As used herein, the phrase "therapeutic
agent" refers to any agent that has a therapeutic effect and/or
elicits a desired biological and/or pharmacological effect, when
administered to a subject.
[0054] "Treatment": As used herein, the term "treatment" (also
"treat" or "treating") refers to any administration of a substance
that partially or completely alleviates, ameliorates, relives,
inhibits, delays onset of, reduces severity of, and/or reduces
incidence of one or more symptoms, features, and/or causes of a
particular disease, disorder, and/or condition. Such treatment may
be of a subject who does not exhibit signs of the relevant disease,
disorder and/or condition and/or of a subject who exhibits only
early signs of the disease, disorder, and/or condition.
Alternatively or additionally, such treatment may be of a subject
who exhibits one or more established signs of the relevant disease,
disorder and/or condition. In some embodiments, treatment may be of
a subject who has been diagnosed as suffering from the relevant
disease, disorder, and/or condition. In some embodiments, treatment
may be of a subject known to have one or more susceptibility
factors that are statistically correlated with increased risk of
development of the relevant disease, disorder, and/or
condition.
[0055] Drawings are presented herein for illustration purposes, not
for limitation.
BRIEF DESCRIPTION OF DRAWINGS
[0056] The foregoing and other objects, aspects, features, and
advantages of the present disclosure will become more apparent and
better understood by referring to the following description taken
in conduction with the accompanying drawings, in which:
[0057] FIG. 1 shows the inverse electron demand Diels-Alder
cycloaddition.
[0058] FIG. 2 shows a schematic of the pretargeted PET imaging
strategy.
[0059] FIG. 3A shows a structure of .sup.64Cu-Tz-NOTA.
[0060] FIG. 3B shows a structure of
.sup.64Cu-Tz-PEG.sub.7-NOTA.
[0061] FIG. 3C shows a structure of .sup.64Cu-Tz-SarAr.
[0062] FIG. 4 shows a schematic of the synthesis of
Tz-PEG.sub.7-NOTA.
[0063] FIG. 5 shows a schematic of the synthesis of Tz-SarAr.
[0064] FIG. 6 shows a schematic of the radiosynthesis of
.sup.64Cu-Tz-PEG.sub.7-NOTA.
[0065] FIG. 7 shows a schematic of the radiosynthesis of
.sup.64Cu-Tz-SarAr.
[0066] FIG. 8 shows a crude radio-HPLC chromatogram of
.sup.64Cu-Tz-PEG.sub.7-NOTA.
[0067] FIG. 9 shows a crude radio-HPLC chromatogram of
.sup.64Cu-Tz-SarAr.
[0068] FIG. 10 shows a schematic of the synthesis of huA33-TCO
[0069] FIG. 11 shows biodistribution data (% ID/g.+-.SD) of
.sup.64Cu-Tz-NOTA, .sup.64Cu-Tz-PEG.sub.7-NOTA, and
.sup.64Cu-Tz-SarAr in healthy athymic nude (n=4 for each time
point). Mice were administered the radioligands (25-30 .mu.Ci in
200 mL 0.9% sterile saline) via intravenous tail vein injection and
euthanized by CO.sub.2(g) asphyxiation at 1, 4, and 24 h after
injection.
[0070] FIG. 12 shows PET imaging data for .sup.64Cu-Tz-NOTA in two
healthy mice. Healthy female athymic nude mice were administered
.sup.64Cu-Tz-NOTA (300-350 .mu.Ci in 200 mL 0.9% sterile saline)
via intravenous tail vein injection (t=0). Approximately 5 minutes
prior to the PET images, mice were anesthetized by inhalation of 2%
isoflurane (Baxter Healthcare, Deerfield, Ill.)/oxygen gas mixture
and placed on the scanner bed; anesthesia was maintained using 1%
isoflurane/gas mixture. Static scans were recorded at various time
points after injection with a minimum of 30 million coincident
events (10-30 min total scan time). Activity concentrations
(percentage of dose per gram of tissue [% ID/g]) and maximum
intensity projections were determined by conversion of the counting
rates from the reconstructed images. All of the resulting PET
images were analyzed using ASIPro VM.TM. software. The coronal
slices above are representative images chosen to illustrate the
areas of highest uptake.
[0071] FIG. 13 shows PET imaging data for .sup.64Cu-Tz-PEG7-NOTA in
two healthy mice. Healthy female athymic nude mice were
administered .sup.64Cu-Tz-PEG.sub.7-NOTA (300-350 .mu.Ci in 200 mL
0.9% sterile saline) via intravenous tail vein injection (t=0).
Approximately 5 minutes prior to the PET images, mice were
anesthetized by inhalation of 2% isoflurane (Baxter Healthcare,
Deerfield, Ill.)/oxygen gas mixture and placed on the scanner bed;
anesthesia was maintained using 1% isoflurane/gas mixture. Static
scans were recorded at various time points after injection with a
minimum of 30 million coincident events (10-30 min total scan
time). Activity concentrations (percentage of dose per gram of
tissue [% ID/g]) and maximum intensity projections were determined
by conversion of the counting rates from the reconstructed images.
All of the resulting PET images were analyzed using ASIPro VM.TM.
software. The coronal slices above are representative images chosen
to illustrate the areas of highest uptake.
[0072] FIG. 14 shows PET imaging data for .sup.64Cu-Tz-SarAr in a
healthy mouse. Healthy female athymic nude mice were administered
.sup.64Cu-Tz-SarAr (300-350 .mu.Ci in 200 .mu.L 0.9% sterile
saline) via intravenous tail vein injection (t=0). Approximately 5
minutes prior to the PET images, mice were anesthetized by
inhalation of 2% isoflurane (Baxter Healthcare, Deerfield,
Ill.)/oxygen gas mixture and placed on the scanner bed; anesthesia
was maintained using 1% isoflurane/gas mixture. Static scans were
recorded at various time points after injection with a minimum of
30 million coincident events (10-30 min total scan time). Activity
concentrations (percentage of dose per gram of tissue [% ID/g]) and
maximum intensity projections were determined by conversion of the
counting rates from the reconstructed images. All of the resulting
PET images were analyzed using ASIPro VM.TM. software. Maximum
intensity projections (MIPs) are shown for each time point, and the
coronal slices above are representative images chosen to illustrate
the areas of highest uptake (i.e. the kidneys, white arrow).
[0073] FIG. 15 shows a plot of the clearance of .sup.64Cu-Tz-SarAr
from the blood vs. time (red squares). Fitting of the data points
to a biexponential function (dotted line) reveals that greater than
99% of the radioligand clears from the blood with a half-life of
.about.16 minutes.
[0074] FIG. 16 shows pretargeted PET imaging using
.sup.64Cu-Tz-SarAr and a 24 h accumulation interval. Female athymic
nude mice (n=5) bearing subcutaneous SW1222 (right shoulder)
xenografts (100-150 mm.sup.3, 9-12 days post-inoculation) were
administered 100 mg (0.66 nmol) huA33-TCO (in 200 mL 0.9% sterile
saline) via intravenous tail vein injection. After an accumulation
interval period of 24 h, the same mice were then administered
.sup.64Cu-Tz-SarAr (400-450 .mu.mCi, 0.66-0.77 nmol, in 200 mL 0.9%
sterile saline), also via intravenous tail vein injection (t=0).
The coronal slices (left) intersect the center of the tumor (white
arrow). Maximum intensity projections (MIP) at 4, 12, and 24 h
post-injection are also displayed (right), as well as a
co-registered PET/CT images collected at 24 h post-injection (far
right, perspective flipped).
[0075] FIG. 17 shows pretargeted PET imaging using
.sup.64Cu-Tz-SarAr and a 24 h accumulation interval. Female athymic
nude mice (n=5) bearing subcutaneous SW1222 (right shoulder)
xenografts (100-150 mm.sup.3, 18-21 days post-inoculation) were
administered 100 mg (0.66 nmol) huA33-TCO (in 200 mL 0.9% sterile
saline) via intravenous tail vein injection. After an accumulation
interval of 24 h, the same mice were then administered
.sup.64Cu-Tz-SarAr (400-450 .mu.Ci in 200 mL 0.9% sterile saline),
also via intravenous tail vein injection (t=0). The specific
activity of .sup.64Cu-Tz-SarAr was adjusted using cold
.sup.natCu-Tz-SarAr such that the molar ratio of
Tz.sub.injected:huA33.sub.Injected=1:1. Static scans were recorded
at various time points after injection with a minimum of 30 million
coincident events (10-30 min total scan time). Activity
concentrations (percentage of dose per gram of tissue [% ID/g]) and
maximum intensity projections were determined by conversion of the
counting rates from the reconstructed images. All of the resulting
PET images were analyzed using ASIPro VM.TM. software. The coronal
slices intersect the center of the tumor, and the maximum intensity
projection (MIP) displayed was collected at 24 h
post-injection.
[0076] FIGS. 18A and 18B show pretargeted PET imaging using
.sup.64Cu-Tz-SarAr and 48 h (18A) and 120 h (18B) accumulation
intervals. The coronal slices (left) intersect the center of the
tumor (white arrow). Maximum intensity projections (MIP) collected
at 24 h post-injection are also displayed (right).
[0077] FIG. 18C shows activity concentration in the tumor as a
function of both time post-injection and accumulation interval for
pretargeting with .sup.64Cu-Tz-SarAr.
[0078] FIG. 18D shows activity concentration in the blood as a
function of both time post-injection and accumulation interval for
pretargeting with .sup.64Cu-Tz-SarAr.
[0079] FIG. 18E shows tumor-to-blood activity concentration ratios
as a function of both time post-injection and accumulation interval
for pretargeting with .sup.64Cu-Tz-SarAr.
[0080] FIG. 18F shows tumor-to-muscle activity concentration ratios
as a function of both time post-injection and accumulation interval
for pretargeting with .sup.64Cu-Tz-SarAr.
[0081] FIG. 19 shows pretargeted PET imaging using
.sup.64Cu-Tz-SarAr and a 48 h accumulation interval. Female athymic
nude mice (n=5 per radioligand) bearing subcutaneous SW1222 (right
shoulder) xenografts (100-150 mm.sup.3, 18-21 days
post-inoculation) were administered 100 mg (0.66 nmol) huA33-TCO
(in 200 mL 0.9% sterile saline) via intravenous tail vein
injection. After an accumulation interval of 48 h, the same mice
were then administered .sup.64Cu-Tz-SarAr (400-450 .mu.Ci in 200 mL
0.9% sterile saline), also via intravenous tail vein injection
(t=0). The specific activity of .sup.64Cu-Tz-SarAr was adjusted
using cold .sup.natCu-Tz-SarAr such that the molar ratio of
Tz.sub.injected:huA33.sub.injected=1:1. Static scans were recorded
at various time points after injection with a minimum of 30 million
coincident events (10-30 min total scan time). Activity
concentrations (percentage of dose per gram of tissue [% ID/g]) and
maximum intensity projections were determined by conversion of the
counting rates from the reconstructed images. All of the resulting
PET images were analyzed using ASIPro VM.TM. software. The coronal
slices intersect the center of the tumor, and the maximum intensity
projection (MIP) displayed was collected at 24 h
post-injection.
[0082] FIG. 20 shows pretargeted PET imaging using
.sup.64Cu-Tz-SarAr and a 120 h accumulation interval. Female
athymic nude mice (n=5) bearing subcutaneous SW1222 (right
shoulder) xenografts (100-150 mm.sup.3, 18-21 days
post-inoculation) were administered 100 mg (0.66 nmol) huA33-TCO
(in 200 mL 0.9% sterile saline) via intravenous tail vein
injection. After an accumulation interval of 120 h, the same mice
were then administered .sup.64Cu-Tz-SarAr (400-450 .mu.Ci in 200 mL
0.9% sterile saline), also via intravenous tail vein injection
(t=0). The specific activity of .sup.64Cu-Tz-SarAr was adjusted
using cold .sup.natCu-Tz-SarAr such that the molar ratio of
Tz.sub.injected:huA33.sub.Injected=1:1. Static scans were recorded
at various time points after injection with a minimum of 30 million
coincident events (10-30 min total scan time). Activity
concentrations (percentage of dose per gram of tissue [% ID/g]) and
maximum intensity projections were determined by conversion of the
counting rates from the reconstructed images. All of the resulting
PET images were analyzed using ASIPro VM.TM. software. The coronal
slices intersect the center of the tumor, and the maximum intensity
projection (MIP) displayed was collected at 24 h
post-injection.
[0083] FIG. 21 shows graphical comparison of salient
tumor-to-tissue activity concentration ratios at 1 h post-injection
created using the different pretargeted PET imaging strategies
discussed (see Tables 11, 14, 16, 18, and 19).
[0084] FIG. 22 shows graphical comparison of salient
tumor-to-tissue activity concentration ratios at 4 h post-injection
created using the different pretargeted PET imaging strategies
discussed (see Tables 11, 14, 16, 18, and 20).
[0085] FIG. 23 shows graphical comparison of salient
tumor-to-tissue activity concentration ratios at 12 h
post-injection created using the different pretargeted PET imaging
strategies discussed (see Tables 11, 14, 16, 18, and 21).
[0086] FIG. 24 shows graphical comparison of salient
tumor-to-tissue activity concentration ratios at 24 h
post-injection created using the different pretargeted PET imaging
strategies discussed (see Tables 11, 14, 16, 18, and 22).
[0087] FIGS. 25A-25H show autoradiography, histology, and
fluorescence microscopy of SW1222 colorectal carcinoma xenografts
resected after pretargeted PET imaging using .sup.64Cu-Tz-SarAr and
an accumulation interval of 120 h.
[0088] FIG. 25A shows hematoxylin and eosin staining
[0089] FIG. 25B shows immunofluorescence staining for the huA33
antibody.
[0090] FIG. 25C shows autoradiography indicating the localization
of .sup.64Cu-Tz-SarAr.
[0091] FIG. 26D shows an overlay of immunofluorescence staining and
autoradiography; (E) higher magnification image of the area
enclosed by the black box in FIG. 25A.
[0092] FIGS. 25F-25H show higher magnification images of the same
area corresponding to FIGS. 25B-25D, respectively.
[0093] FIG. 26 shows pretargeted PET imaging using
.sup.64Cu-Tz-NOTA. Female athymic nude mice (n=5) bearing
subcutaneous SW1222 (right shoulder) xenografts (100-150 mm.sup.3,
18-21 days post-inoculation) were administered 100 mg (0.66 nmol)
huA33-TCO (in 200 mL 0.9% sterile saline) via intravenous tail vein
injection. After an accumulation interval of 24 h, the same mice
were then administered .sup.64Cu-Tz-NOTA (400-450 .mu.Ci in 200 mL
0.9% sterile saline), also via intravenous tail vein injection
(t=0). The specific activity of .sup.64Cu-Tz-NOTA was adjusted
using cold .sup.natCu-Tz-NOTA such that the molar ratio of
Tz.sub.injected:huA33.sub.injected=1:1. Static scans were recorded
at various time points after injection with a minimum of 30 million
coincident events (10-30 min total scan time). Activity
concentrations (percentage of dose per gram of tissue [% ID/g]) and
maximum intensity projections were determined by conversion of the
counting rates from the reconstructed images. All of the resulting
PET images were analyzed using ASIPro VM.TM. software. The coronal
slices intersect the center of the tumor (solid white arrow), and
the maximum intensity projection (MIP) displayed was collected at
24 h post-injection. Note the activity not only in the SW1222
xenograft but also in the gut of the mouse (dashed white arrow) at
4 h post-injection.
[0094] FIG. 27 shows the radiochemical synthesis of the radioligand
Tz-PEG.sub.11-Al.sup.18F-NOTA ([.sup.18F]2). [.sup.18F]2 was
obtained in 54-56% radiochemical yields (RCY) (d.c.) and high
specifica activities (SAs) (21.4-26.7 GBq/.mu.mol) after a total
synthesis time of 108 min. Purification of the crude reaction
mixture using a C18-cartridge gave [.sup.18F]2 in purities of
greater than 96%.
[0095] FIG. 28 shows results of the biodistribution pretargeting
CA19.9 with [.sup.18F]2/5B1-TCO. Subcutaneous BxPC3 xenograft
bearing mice were administered 5B1-TCO (1.33 nmol) 72 h prior to
the injection of the .sup.18F-labeled tracer (1.33 nmol, 1.8-2.0
MBq) via the tail vein before the mice were euthanized and the
organs collected at the appropriate time points.
[0096] FIG. 29 shows PET images of
Tz-PEG.sub.11-NOTA-Al.sup.18F/5B1-TCO pretargeting strategy.
Subcutaneous BxPC3 xenograft bearing mice were administered 5B1-TCO
(1.33 nmol) 72 h prior to the injection of the .sup.18F-labeled
tracer (1.33 nmol, 18-20 MBq) via the tail vein. Transverse (top)
and coronal (middle) planar images intersect the center of the
tumors. The maximum intensity projections (MIPs, bottom) clearly
illustrate tumor uptake after 1 h with increasing
tumor-to-background ratios over the course of the experiment.
[0097] FIGS. 30A and 30B show radioactivity (FIG. 30A) and UV (FIG.
30B) traces of the radio-HPLC analysis of the radioligand
Tz-PEG.sub.11-Al[.sup.18F]-NOTA.
[0098] FIGS. 31A and 31B show radio-TLC diagrams using 90% MeCN in
H.sub.2O as mobile phase showing free radioligand (FIG. 31A) and
the click reaction product after 15 min incubation (FIG. 31B) at
room temperature of the radioligand with TCO-modified 5B1. The
results indicated that the click reaction is complete after 15 min
(n=3).
[0099] FIG. 32 shows biodistribution data of the radioligand
obtained from healthy nude mice at 1, 2, and 4 h (n=4) after
injection of the radioligand [.sup.18F]2.
[0100] FIG. 33 shows the blood half-life of the radioligand was
calculated by plotting the % ID/g of the collected blood samples
for each time point (n=4) against the corresponding collection time
points.
DETAILED DESCRIPTION
[0101] Throughout the description, where compositions are described
as having, including, or comprising specific components, or where
methods are described as having, including, or comprising specific
steps, it is contemplated that, additionally, there are
compositions of the present invention that consist essentially of,
or consist of, the recited components, and that there are methods
according to the present invention that consist essentially of, or
consist of, the recited processing steps.
[0102] It should be understood that the order of steps or order for
performing certain action is immaterial so long as the invention
remains operable. Moreover, two or more steps or actions may be
conducted simultaneously.
[0103] The mention herein of any publication, for example, in the
Background section, is not an admission that the publication serves
as prior art with respect to any of the claims presented herein.
The Background section is presented for purposes of clarity and is
not meant as a description of prior art with respect to any
claim.
[0104] Described herein are Tz/TCO-based pretargeting strategies
using (1) a .sup.64Cu-sarcophagine-based tetrazine radioligand for
pretargeted PET imaging with more rapid excretion of the excess
radioligand through the bladder and kidneys and (2) an
Al[.sup.18F]-NOTA-labeled tetrazine radioligand. These imaging
strategies enable delineation of cancer at earlier time points
compared to other imaging strategies and further decrease the
radiation dose to healthy tissues compared to directly labeled
antibodies.
[0105] In certain embodiments, two radioligands
.sup.64Cu-Tz-PEG.sub.7-NOTA and .sup.64Cu-Tz-SarAr--based on
.sup.64Cu-Tz-NOTA were designed to harbor structural modifications
to alter the pharmacokinetics of .sup.64Cu-Tz-NOTA. The in vivo
evaluation of these two constructs revealed that
.sup.64Cu-Tz-PEG.sub.7-NOTA was eliminated via both the
gastrointestinal and renal tracts and .sup.64Cu-Tz-SarAr was
cleared through the renal system alone. Moreover, pretargeted PET
imaging and biodistribution experiments using huA33-TCO,
.sup.64Cu-Tz-SarAr, and mice bearing human colorectal carcinoma
xenografts revealed that this approach delineated malignant tissue
with high tumor-to-background contrast at only a fraction of the
radiation dose created by traditional, directly-labeled
radioimmunoconjugates. Altering the molecular structure of the
tetrazine-bearing radioligand effectively eliminated background
uptake of the radioligand in the gastrointestinal tract.
[0106] In certain embodiments, a TCO-bearing immuno-conjugate of
the anti-CA19.9 antibody 5B1 and an Al[.sup.18F]-NOTA-labeled
tetrazine radioligand were harnessed for the visualization of
CA19.9-expressing BxPC3 pancreatic cancer xenografts. Al-based
.sup.18F imaging of small molecules, such as tetrazine, has not
been previously achieved due to the decomposition of tetrazine
during radiofluorination. Radiofluorination is advantageous over
other radiolabeling methods because, in addition to having a
shorter half-life, .sup.18F is more readily available to produce
and therefore more convenient to integrate into hospital workflows.
Biodistribution and .sup.18F-PET imaging data demonstrate that this
methodology effectively delineates tumor mass with activity
concentrations up to 6.4% ID/g at 4 h after injection of the
radioligand.
.sup.64Cu-Based Tetrazine Radioligands for Pretargeted Imaging
[0107] The present disclosure describes the synthesis and
characterization of the in vivo behavior of two .sup.64Cu-labeled
tetrazine radioligands--.sup.64Cu-Tz-PEG.sub.7-NOTA and
.sup.64Cu-Tz-SarAr--that possess structural alterations to modulate
their pharmacokinetic profiles. It was found that the
.sup.64Cu-Tz-SarAr radioligand, in combination with the huA33-TCO,
performed better than the .sup.64Cu-Tz-NOTA radioligand. For
example, the combined huA33-TCO and .sup.64Cu-Tz-SarAr system
exhibited higher activity concentrations in the tumor, the
.sup.64Cu-Tz-SarAr radioligand was rapidly cleared through the
renal system allowing for higher tumor-to-background activity
concentration ratios at early time points, and the presently
described system demonstrated dosimetric improvement over other
radioimmunoconjugate systems.
System Design
[0108] At a basic level, the pretargeting strategy described herein
comprises three components: (1) the antibody, (2) the
transcyclooctene, and (3) the tetrazine; each component is
important. The present disclosure describes a pretargeted PET
imaging system for colorectal system, which uses the huA33
antibody. The huA33 antibody is a humanized antibody that targets
the A33 antigen, a transmembrane glycoprotein abundantly expressed
by greater than 95% of all colorectal cancer tumors. While low
levels of expression of the A33 antigen have been found on normal
bowel epithelium, clinical studies with .sup.124I-labeled huA33
have illustrated that tumor tissue retains the antibody far longer
than healthy epithelium. Furthermore, in vitro studies have shown
that the huA33-A33 antigen complex persists on the surface of the
cell for days after formation. These features are important for
pretargeting methodologies because the antibody must accumulate in
tumor tissue compared to normal tissue and remain accessible to the
radioligand for the in vivo ligation to occur.
[0109] The pretargeted PET system includes: (1) injection of the
huA33-TCO conjugate; (2) accumulation of the antibody at the target
site and allowing unbound antibody to clear from the blood; (3)
injection of the radioligand; and (4) an in vivo click ligation of
the two components, followed by clearance of the excess radioligand
(FIG. 2). Importantly, this pretargeting strategy effectively
delineates tumor tissue at much earlier time points than directly
radiolabeled antibodies and significantly reduces the overall
radiation burden to the patient, permitting safer and more accurate
diagnoses in shorter time frames.
[0110] The present disclosure also describes use of
transcyclooct-4-en-1-yl hydrogen carbonate (TCO) and
3-4-(benzylamine)-1,2,4,5-tetrazine (Tz) as the transcyclooctene
and tetrazine components. The IEDDA cycloaddition between these two
moieties has been shown to be extraordinarily rapid, with a second
order rate constant greater than 30,000M.sup.-1 s.sup.-1.
Furthermore, both components have been shown to be sufficiently
stable in physiological settings, and amine-reactive variants
(TCO-NHS and Tz-NHS) of both are commercially available.
[0111] As described above, the relatively slow (t.sub.1/2.about.4
h) clearance of the .sup.64Cu-Tz-NOTA (FIG. 3A) through the
intestinal tract has hampered potential use as a methodology for
imaging colorectal cancer. Without being bound by theory, it is
thought that PEG linkers--also known as oligoethyleneglycol
linkers--can accelerate the clearance and lower the non-target
tissue uptake of radiopharmaceuticals. Likewise, without being
bound by theory, it is thought that changes to the identity of the
chelator and the overall charge of the radiometal-chelator complex
can dramatically influence pharmacokinetics. Thus, two .sup.64Cu-Tz
radioligands with structural alterations made to .sup.64Cu-Tz-NOTA
were designed for improved pharmacokinetic profiles. To this end,
two different structural motifs (e.g., polyethyleneglycol (PEG)
linkers and chelators) were used to influence the in vivo behavior
of radiotracers.
[0112] In a first example disclosed herein,
.sup.64Cu-Tz-PEG.sub.7-NOTA contained a PEG.sub.7 spacer that
separated the tetrazine moiety from the NOTA chelator (FIG. 3B). In
a second example disclosed herein, .sup.64Cu-Tz-SarAr contained a
sarcophagine-based chelator (SarAr) that replaced the NOTA
macrocycle. This chelator substitution not only changed the
coordination environment from N.sub.3O.sub.3 to N.sub.6 but shifted
the overall charge of the metal-ligand complex from -1
(Cu.sup.II-NOTA) to +2 (Cu.sup.II-SarAr) (FIG. 3C). Table 0 depicts
some selected properties of the three tetrazine radioligands shown
in FIGS. 3A-3C.
TABLE-US-00001 TABLE 0 % Intact % Intact Molecular After 2 h After
2 h weight Coordination Net @ 37.degree. C. @ 37.degree. C.
Radioligand (MW) Environment Charge Log D (PBS) (Serum)
.sup.64Cu-Tz- 752.6 N.sub.3O.sub.3 -1 -2.54 +/- 0.10 91.6 +/- 1.9
85.4 +/- 6.6 NOTA .sup.64Cu-Tz- 1163.2 N.sub.3O.sub.3 -1 -2.44 +/-
0.08 87.0 +/- 1.3 84.7 +/- 4.8 PEG.sub.7-NOTA .sup.64Cu-Tz- 780.9
N.sub.6 +2 -2.08 +/- 0.06 94.7 +/- 0.6 92.0 +/- 2.1 SarAr
Synthesis and Characterization
[0113] Tz-PEG.sub.7-NOTA was synthesized in 49% yield over three
facile steps: the coupling of Tz-NHS and monofunctional
O-(2-aminoethyl)-O'-[2-(bocamino)ethyl]hexaethylene glycol to form
Tz-PEG.sub.7-NHBoc; the removal of the tert-butyloxycarbonyl
protecting group with TFA/CH.sub.2Cl.sub.2; and the coupling of
Tz-PEG.sub.7-NH.sub.2 with p-NCS-Bn-NOTA (FIG. 4). Given the
symmetry of its sarcophagine precursor, Tz-SarAr required more
complex synthesis. In this case, the mono-alkylation of DiAmSar
with Boc-protected 4-(bromomethyl)-benzylamine was followed by the
removal of the acid-labile protecting group with TFA and the
coupling of the resulting SarAr-Bn-NH.sub.2 moiety with Tz-NHS to
produce the final product in 29% yield over three steps (FIG. 5).
For both syntheses, all intermediates as well as the completed
tetrazine-bearing precursors were analyzed and purified using
reverse-phase C.sub.18 HPLC and characterized via UV-Vis
spectrophotometry, .sup.1H-NMR, ESI-MS, and high-resolution mass
spectrometry.
[0114] Once the precursors were made, the tetrazine constructs were
then radiolabeled via incubation with [.sup.64Cu]--CuCl.sub.2 for
10 minutes at room temperature in 200 mM NH.sub.4OAc, pH 5.0 and
purified via reverse-phase C.sub.18 HPLC (t.sub.R=8.7 min for
.sup.64Cu-Tz-SarAr and 9.7 min for .sup.64Cu-Tz-PEG.sub.7NOTA;
FIGS. 6-9). In both cases, the identity of the radiolabeled product
was confirmed via co-injection of unlabeled .sup.natCu-Tz-SarAr and
.sup.natCu-Tz-PEG.sub.S-NOTA standards. Ultimately,
.sup.64Cu-Tz-PEG.sub.7NOTA was prepared in greater than 99%
radionuclidic purity, 78.+-.6% decay-corrected isolated yield, and
a specific activity of 323.+-.37 mCi/.mu.mol (n=6). Similarly,
.sup.64Cu-Tz-SarAr was synthesized in greater than 99%
radionuclidic purity, 79.+-.7% decay-corrected isolated yield, and
a specific activity of 310.+-.36 mCi/.mu.mol (n=6). The
.sup.64Cu-Tz-NOTA radioligand was synthesized, radiolabeled, and
purified as previously reported by Zeflis et al. J. Nucl. Med.
2013, 54, 1389-1396, which is hereby incorporated by reference in
its entirety. In order to probe the influence of the structural
changes on solubility, the partition coefficients of the various
radioligands were determined using PBS (pH 7.4) and 1-octanol
(Table 1). Table 1 shows partition coefficient (Log D) of the
.sup.64Cu-labeled tetrazines in 1-octanol and PBS (pH 7.4). While
all three radioligands proved reasonably hydrophilic (e.g., log D
values below -2), differences were observed. For example, the
replacement of NOTA with SarAr rendered .sup.64Cu-Tz-SarAr (log
D=-2.08.+-.0.06) more hydrophobic than .sup.64Cu-Tz-NOTA (log
D=-2.54.+-.0.1). Moreover, the addition of the PEG.sub.7 moiety in
.sup.64Cu-Tz-PEG.sub.7-NOTA did not generate a more hydrophilic
product (log D=-2.44.+-.0.08) than the .sup.64Cu-Tz-NOTA
radioligand that lacked a linker.
TABLE-US-00002 TABLE 1 Radioligand LogD .sup.64Cu-Tz-NOTA -2.54
.+-. 0.10 .sup.64Cu-Tz-PEG.sub.7-NOTA -2.44 .+-. 0.08
.sup.64Cu-Tz-SarAr -2.08 .+-. 0.06
[0115] Next, the aqueous and serum stabilities were determined via
incubation at 37.degree. C. (Tables 2-3). Both
.sup.64Cu-Tz-PEG.sub.7-NOTA and .sup.64Cu-Tz-SarAr were shown to be
fairly stable in PBS (pH 7.4). It was determined that 94.7.+-.0.6%
and 93.3.+-.0.5% of .sup.64Cu-Tz-SarAr remained intact after 2 and
4 h, respectively. .sup.64Cu-Tz-PEG.sub.7-NOTA proved similarly
stable, with 87.0.+-.1.3% (2 h) and 83.2.+-.4.6% (4 h) intact.
However, more extensive decomposition was observed in human serum.
For example, after a 4 h incubation, 77.8.+-.3.5% and 81.2.+-.3.7%
of .sup.64Cu-Tz-PEG.sub.S-NOTA and .sup.64Cu-Tz-SarAr,
respectively, remained intact. Importantly, the release of
.sup.64CU.sup.2+ from the chelators was not observed in any of the
trials. Despite the rates of decomposition, the speed of the IEDDA
reaction was faster than short blood half-lives of these small
molecules; therefore, the radioligands remained functional in vivo.
Table 2 shows the percent of .sup.64Cu-Tz-PEG.sub.7-NOTA and
.sup.64Cu-Tz-SarAr intact after incubation in PBS (pH 7.4) at
37.degree. C. Table 3 shows the percent of
.sup.64Cu-Tz-PEG.sub.7-NOTA and .sup.64Cu-Tz-SarAr intact after
incubation in human serum at 37.degree. C.
TABLE-US-00003 TABLE 2 .sup.64Cu-Tz-PEG.sub.7- Time NOTA
.sup.64Cu-Tz-SarAr 2 h 87.0 .+-. 1.3 94.7 .+-. 0.6 4 h 83.2 .+-.
4.6 93.3 .+-. 0.5 8 h 76.2 .+-. 2.6 89.7 .+-. 2.3
TABLE-US-00004 TABLE 3 .sup.64Cu-Tz-PEG.sub.7- Time NOTA
.sup.64Cu-Tz-SarAr 2 h 84.7 .+-. 4.8 92.0 .+-. 2.1 4 h 77.8 .+-.
3.5 81.2 .+-. 3.7 8 h 64.0 .+-. 6.5 67.7 .+-. 4.3
[0116] Next, huA33-TCO was synthesized via the coupling of TCO-NHS
to the huA33 antibody as previously described (FIG. 10). Briefly, a
solution of huA33 (2-3 mg/mL) in PBS was adjusted to pH 8.8-9.0
with 0.1 M Na.sub.2CO.sub.3. Ten molar equivalents of TCO-NHS were
then added to the antibody solution, and the resulting reaction
mixture was incubated at room temperature for 1 hr prior to
purification via size exclusion chromatography. Using a
fluorophore-labeled tetrazine probe (Tz-PEG.sub.7-AF680), the TCO
occupancy of the huA33 was determined to be 3.6.+-.0.6 TCO/mAb.
Both .sup.64Cu-Tz-PEG.sub.7-NOTA and .sup.64Cu-Tz-SarAr were
incubated with huA33-TCO and rapidly resulted in greater than 95%
reaction yields. After purification, .sup.64Cu-labeled huA33
radioimmunoconjugates exhibited high specific activities (greater
than 2 mCi/mg) and immunoreactive fractions (greater than 0.95)
with A33 antigen-expressing SW1222 human colorectal carcinoma cells
(Table 4). Control reactions between unmodified huA33 and the
.sup.64Cu-labeled tetrazines as well as huA33-TCO and uncomplexed
.sup.64CU.sup.2+ resulted in less than 1% radiolabeling of the
huA33 constructs. Table 4 shows immunoreactive fractions of
radioimmunoconjugates formed through the reaction of huA33-TCO and
either .sup.64Cu-Tz-PEG.sub.7-NOTA or .sup.64Cu-Tz-SarAr, as
determined via in vitro assays with A33 antigen-expressing SW1222
cells.
TABLE-US-00005 TABLE 4 Immunoreactive Radioimmunoconjugate Fraction
huA33-TCO + .sup.64Cu-Tz-PEG.sub.7- 0.96 .+-. 0.02 NOTA huA33-TCO +
.sup.64Cu-Tz-SarAr 0.97 .+-. 0.01
In Vivo Evaluation of the .sup.64 Cu-Labeled Tetrazines
[0117] After synthesis and characterization, in vivo behavior and
pharmacokinetics of the .sup.64Cu-labeled tetrazine radioligands
were measured. To this end, acute biodistribution and PET imaging
experiments were performed in healthy athymic nude mice injected
with .sup.64Cu-Tz-NOTA, .sup.64Cu-Tz-PEG.sub.7-NOTA, or
.sup.64Cu-Tz-SarAr (FIGS. 12-14 and Tables 5-7). All three
.sup.64Cu-labeled tetrazines minimally accumulated in most healthy
non-target tissues, with activity concentrations lower than 0.5%
ID/g beyond the earliest time points. Notably, the largest
difference between the three radioligands was their excretion
profiles. As discussed previously, .sup.64Cu-Tz-NOTA was excreted
relatively slowly through the feces, with 10.0.+-.1.3% ID/g
remaining in the large intestine and its contents at 4 h
post-injection, a number which dropped to 1.4.+-.0.7% ID/g at 24 h.
The addition of the PEG linker in .sup.64Cu-Tz-PEG.sub.7-NOTA
caused two distinct changes. First, the elimination of the
radioligand through the gut was accelerated, with only 4.9.+-.0.7%
ID/g in the large intestine and its contents at 4 h post-injection
Second, the kidneys displayed activity concentrations of
1.5.+-.0.2% ID/g and 1.2.+-.0.4% ID/g at 1 h and 4 h, respectively,
indicating that a portion of the radiotracer was excreted by the
urinary tract. Notably, the largest difference was observed with
.sup.64Cu-Tz-SarAr, which was excreted exclusively and rapidly
through the renal system. The tissue with the highest levels of
.sup.64Cu-Tz-SarAr at 1 h post-injection was the kidney, with
2.3.+-.0.4% ID/g. The activity in the kidneys decreased over time;
however, at 24 h some retention of the radioligand remained.
Complementary PET imaging experiments confirmed the observations
from the biodistributions: .sup.64Cu-Tz-SarAr cleared quickly and
cleanly through the urinary tract; .sup.64Cu-Tz-NOTA was eliminated
somewhat sluggishly through the gastrointestinal pathway; and
.sup.64Cu-Tz-PEG.sub.7-NOTA represented an intermediate case, with
excretion through both the intestines and the kidneys.
[0118] Table 5 shows biodistribution data (% ID/g.+-.SD) of
.sup.64Cu-Tz-NOTA versus time in healthy athymic nude (n=4 for each
time point). Mice were administered .sup.64Cu-Tz-NOTA (25-30 .mu.Ci
in 200 .mu.L, 0.9% sterile saline) via intravenous tail vein
injection. Animals (n=4 per group) were euthanized by CO.sub.2(g)
asphyxiation at 1, 4, and 24 h after injection. After asphyxiation,
tissues were removed, rinsed in water, dried in air for 5 min,
weighed, and counted in a gamma counter calibrated for .sup.64Cu.
Counts were converted into activity using a calibration curve
generated from known standards. Count data were background- and
decay-corrected to the time of injection, and the percent injected
dose per gram (% ID/g) for each tissue sample was calculated by
normalization to the total activity injected. Contents within the
stomach, small intestine, and large intestine were not removed for
the measurements.
TABLE-US-00006 TABLE 5 1 h 4 h 24 h Blood 0.23 .+-. 0.01 0.13 .+-.
0.01 0.07 .+-. 0.01 Heart 0.10 .+-. 0.02 0.11 .+-. 0.02 0.09 .+-.
0.01 Lung 0.38 .+-. 0.06 0.27 .+-. 0.08 0.21 .+-. 0.02 Liver 1.45
.+-. 0.39 0.42 .+-. 0.13 0.21 .+-. 0.06 Spleen 0.15 .+-. 0.05 0.09
.+-. 0.02 0.08 .+-. 0.02 Stomach 0.12 .+-. 0.04 0.05 .+-. 0.03 0.18
.+-. 0.11 Large Intestine 11.58 .+-. 2.19 10.03 .+-. 1.33 1.37 .+-.
0.65 Small Intestine 3.14 .+-. 1.47 0.17 .+-. 0.07 0.10 .+-. 0.02
Kidney 0.53 .+-. 0.09 0.33 .+-. 0.07 0.22 .+-. 0.07 Muscle 0.04
.+-. 0.02 0.03 .+-. 0.02 0.03 .+-. 0.03 Bone 0.10 .+-. 0.03 0.07
.+-. 0.04 0.03 .+-. 0.01
[0119] Table 6 shows biodistribution data (% ID/g.+-.SD) of
.sup.64Cu-Tz-PEG.sub.7-NOTA versus time in healthy athymic nude
(n=4 for each time point). Mice were administered
.sup.64Cu-Tz-PEG.sub.7-NOTA (25-30 .mu.Ci in 200 .mu.L, 0.9%
sterile saline) via intravenous tail vein injection. Animals (n=4
per group) were euthanized by CO.sub.2(g) asphyxiation at 1, 4, and
24 h after injection. After asphyxiation, tissues were removed,
rinsed in water, dried in air for 5 min, weighed, and counted in a
gamma counter calibrated for .sup.64Cu. Counts were converted into
activity using a calibration curve generated from known standards.
Count data were background- and decay-corrected to the time of
injection, and the percent injected dose per gram (% ID/g) for each
tissue sample was calculated by normalization to the total activity
injected. Contents within the stomach, small intestine, and large
intestine were not removed for the measurements.
TABLE-US-00007 TABLE 6 1 h 4 h 24 h Blood 0.38 .+-. 0.14 0.26 .+-.
0.14 0.08 .+-. 0.01 Heart 0.17 .+-. 0.02 0.18 .+-. 0.03 0.09 .+-.
0.01 Lung 0.49 .+-. 0.11 0.35 .+-. 0.13 0.17 .+-. 0.03 Liver 0.77
.+-. 0.11 0.63 .+-. 0.2 0.32 .+-. 0.11 Spleen 0.19 .+-. 0.01 0.14
.+-. 0.02 0.12 .+-. 0.01 Stomach 0.18 .+-. 0.06 0.36 .+-. 0.25 0.09
.+-. 0.02 Large Intestine 6.35 .+-. 0.69 4.91 .+-. 0.71 0.40 .+-.
0.15 Small Intestine 0.5 .+-. 0.26 0.3 .+-. 0.14 0.10 .+-. 0.01
Kidney 1.51 .+-. 0.24 1.23 .+-. 0.39 0.86 .+-. 0.11 Muscle 0.05
.+-. 0.01 0.03 .+-. 0.02 0.02 .+-. 0.01 Bone 0.09 .+-. 0.06 0.07
.+-. 0.02 0.06 .+-. 0.01
[0120] Table 7 shows biodistribution data (% ID/g.+-.SD) of
.sup.64Cu-Tz-SarAr versus time in healthy athymic nude (n=4 for
each time point). Mice were administered .sup.64Cu-Tz-SarAr (25-30
.mu.Ci in 200 .mu.L 0.9% sterile saline) via intravenous tail vein
injection. Animals (n=4 per group) were euthanized by CO.sub.2(g)
asphyxiation at 1, 4, and 24 h after injection. After asphyxiation,
tissues were removed, rinsed in water, dried in air for 5 min,
weighed, and counted in a gamma counter calibrated for .sup.64Cu.
Counts were converted into activity using a calibration curve
generated from known standards. Count data were background- and
decay-corrected to the time of injection, and the percent injected
dose per gram (% ID/g) for each tissue sample was calculated by
normalization to the total activity injected. Contents within the
stomach, small intestine, and large intestine were not removed for
the measurements.
TABLE-US-00008 TABLE 7 1 h 4 h 24 h Blood 0.42 .+-. 0.11 0.15 .+-.
0.01 0.06 .+-. 0.01 Heart 0.22 .+-. 0.06 0.12 .+-. 0.02 0.08 .+-.
0.02 Lung 0.32 .+-. 0.06 0.31 .+-. 0.09 0.24 .+-. 0.06 Liver 0.72
.+-. 0.03 0.42 .+-. 0.24 0.28 .+-. 0.07 Spleen 0.38 .+-. 0.06 0.2
.+-. 0.05 0.21 .+-. 0.04 Stomach 0.24 .+-. 0.14 0.2 .+-. 0.1 0.05
.+-. 0.01 Large Intestine 0.07 .+-. 0.01 0.08 .+-. 0.03 0.07 .+-.
0.01 Small Intestine 0.29 .+-. 0.21 0.16 .+-. 0.03 0.07 .+-. 0.01
Kidney 2.34 .+-. 0.35 1.57 .+-. 0.19 1.26 .+-. 0.41 Muscle 0.05
.+-. 0.03 0.04 .+-. 0.01 0.03 .+-. 0.01 Bone 0.12 .+-. 0.03 0.09
.+-. 0.01 0.08 .+-. 0.02
[0121] Thus, .sup.64Cu-Tz-SarAr possessed improved elimination
pharmacokinetics compared to other pretargeted PET strategies. The
radioligand was excreted rapidly via the bladder and kidneys, and
the activity concentrations in the large intestine--a critical
source of background noise in clinical colorectal cancer
imaging--remained remarkably low (e.g., 0.07.+-.0.01% ID/g at 1 h
post-injection). Additional experiments were conducted to further
interrogate the in vivo performance of .sup.64Cu-Tz-SarAr. Blood
activity measurements, for example, revealed that the vast majority
of the radioligand cleared from the blood with a residence time of
.about.16 minutes (see Table 8 and FIG. 15). Moreover, in vivo
stability assays indicated that 96.8.+-.0.8% of the
.sup.64Cu-Tz-SarAr remained intact at 15 minutes post-injection, a
value which falls to 82.0.+-.3.3% at 1 h post-injection and
ultimately 29.0.+-.5.9% 4 h after administration (see Table 9).
These numbers clearly indicated that while .sup.64Cu-Tz-SarAr was
not tremendously stable in vivo, the radioligand unquestionably
remained intact during the critical initial blood residence time
frame.
[0122] Table 8 shows the in vivo blood residence time of
.sup.64Cu-Tz-SarAr in healthy athymic nude mice (n=3).
TABLE-US-00009 TABLE 8 Time Activity in Blood (% ID/g) 15 min 3.02
.+-. 1.10 30 min 1.55 .+-. 0.21 1 h 0.42 .+-. 0.11 4 h 0.15 .+-.
0.01 12 h 0.12 .+-. 0.03 24 h 0.06 .+-. 0.01
[0123] Table 9 shows percent of .sup.64Cu-Tz-SarAr intact in blood
after vs. time.
TABLE-US-00010 TABLE 9 % Intact .sup.64Cu-Tz- Time SarAr 15 min
96.8 .+-. 0.8 1 h 82.0 .+-. 3.3 4 h 29.0 .+-. 5.9
In Vivo Pretargeting
[0124] Due to its pharmacokinetic profile, .sup.64Cu-Tz-SarAr was
selected for in vivo pretargeting experiments. To this end, athymic
nude mice bearing A33 antigen-expressing SW1222 human colorectal
carcinoma tumors were first injected with huA33-TCO (100 .mu.g).
After a 24 h interval during which huA33-TCO accumulated at the
tumor and cleared from the blood, the mice were injected with
.sup.64Cu-Tz-SarAr (400-450 .mu.Ci). The specific activity of the
radiotracer was adjusted using cold .sup.natCu-Tz-SarAr such that
the molar ratio of Tz-SarAr:huA33-TCO.apprxeq.1:1. Both the PET
imaging (FIG. 16 and FIG. 17) and biodistribution results (Tables
10-12) indicated that the strategy quickly and clearly delineated
colorectal carcinoma tissue with low activity concentrations in
non-target tissues. At 1 h post-injection, the activity
concentration in the tumor (5.63.+-.0.67% ID/g) was the highest of
all tissues surveyed, while the blood (4.2.+-.0.8% ID/g) and
kidneys (3.1.+-.0.3% ID/g) were the healthy organs with the highest
background activity concentrations. Notably, over the course of the
experiment, the activity in the non-target tissues cleared. For
example, at 24 h post-injection, the activity concentration in the
blood and kidneys was reduced to 2.2.+-.0.4% ID/g and 1.9.+-.0.4%
ID/g, respectively, while the tumoral activity concentration at the
same time point was 6.7.+-.1.3% ID/g. Furthermore, all other
non-target tissues contained less than 1.5% ID/g at these later
time points. Moreover, the tumor-to-background activity ratios were
favorable at early time points (e.g., tumor:muscle=14.9.+-.2.9 at 1
h post-injection) and increased to 45.12.+-.8.5 at 12 h and
37.37.+-.16.1 at 24 h (Table 11). Control PET imaging experiments
were run using .sup.64Cu-Tz-SarAr alone as well as
.sup.64Cu-Tz-SarAr with unmodified huA33. As expected, both cases
resulted in minimal (less than 0.5% ID/g) uptake by the tumor.
[0125] Table 10 shows the biodistribution of .sup.64Cu-Tz-SarAr
pretargeting experiment with a 24 h accumulation interval. Female
athymic nude mice bearing subcutaneous SW1222 (right shoulder)
xenografts (100-150 mm.sup.3, 18-21 days post-inoculation) were
administered 100 .mu.g (0.66 nmol) huA33-TCO (in 200 .mu.L, 0.9%
sterile saline) via intravenous tail vein injection. After an
accumulation interval of 24 h, the same mice were then administered
.sup.64Cu-Tz-SarAr (300-350 .mu.Ci in 200 .mu.L, 0.9% sterile
saline), also via intravenous tail vein injection (t=0). The
specific activity of the radiotracer was adjusted using cold
.sup.natCu-Tz-SarAr such that the molar ratio of
Tz.sub.injected:huA33.sub.Injected=1:1. Animals (n=4 per group)
were euthanized by CO.sub.2(g) asphyxiation at 1, 4, 12, and 24 h
after injection. After asphyxiation, 13 tissues were removed,
rinsed in water, dried in air for 5 min, weighed, and counted in a
gamma counter calibrated for .sup.64Cu. Counts were converted into
activity using a calibration curve generated from known standards.
Count data were background- and decay-corrected to the time of
injection, and the percent injected dose per gram (% ID/g) for each
tissue sample was calculated by normalization to the total activity
injected. Contents within the stomach, small intestine, and large
intestine were not removed for the measurements.
TABLE-US-00011 TABLE 10 1 h 4 h 12 h 24 h Blood 4.20 .+-. 0.80 4.00
.+-. 0.37 2.19 .+-. 0.39 2.61 .+-. 0.20 Tumor 5.63 .+-. 0.67 5.56
.+-. 0.91 6.74 .+-. 1.26 7.38 .+-. 2.02 Heart 1.81 .+-. 0.46 1.45
.+-. 0.03 0.84 .+-. 0.1 0.81 .+-. 0.04 Lung 1.65 .+-. 0.51 1.55
.+-. 0.45 1.24 .+-. 0.22 0.99 .+-. 0.24 Liver 1.60 .+-. 0.12 1.45
.+-. 0.21 1.33 .+-. 0.53 1.51 .+-. 0.2 Spleen 0.98 .+-. 0.25 0.81
.+-. 0.20 0.65 .+-. 0.17 0.64 .+-. 0.04 Stomach 0.73 .+-. 0.19 0.56
.+-. 0.20 0.21 .+-. 0.1 0.28 .+-. 0.07 Large Intestine 0.21 .+-.
0.09 0.48 .+-. 0.09 0.20 .+-. 0.04 0.26 .+-. 0.06 Small Intestine
0.88 .+-. 0.09 0.62 .+-. 0.06 0.35 .+-. 0.08 0.45 .+-. 0.07 Kidney
3.08 .+-. 0.28 2.77 .+-. 0.57 1.87 .+-. 0.42 2.00 .+-. 0.24 Muscle
0.38 .+-. 0.06 0.37 .+-. 0.07 0.15 .+-. 0.01 0.20 .+-. 0.07 Bone
0.67 .+-. 0.14 0.34 .+-. 0.18 0.23 .+-. 0.05 0.29 .+-. 0.05
[0126] Table 11 shows tumor-to-tissue activity concentration ratios
derived from the .sup.64Cu-Tz-SarAr pretargeting biodistribution
experiment with a 24 h accumulation interval as shown in Table
10.
TABLE-US-00012 TABLE 11 1 h 4 h 12 h 24 h Tumor/Blood 1.34 .+-.
0.30 1.39 .+-. 0.26 3.07 .+-. 0.79 2.83 .+-. 0.81 Tumor/Heart 3.11
.+-. 0.87 3.84 .+-. 0.63 8.01 .+-. 1.77 9.10 .+-. 2.54 Tumor/Lung
3.40 .+-. 1.12 3.59 .+-. 1.20 5.43 .+-. 1.41 7.44 .+-. 2.74
Tumor/Liver 3.52 .+-. 0.49 3.83 .+-. 0.83 5.06 .+-. 2.23 4.87 .+-.
1.48 Tumor/Spleen 5.75 .+-. 1.61 6.88 .+-. 2.01 10.34 .+-. 3.27
11.45 .+-. 3.20 Tumor/Stomach 7.75 .+-. 2.24 9.91 .+-. 3.85 31.76
.+-. 16.62 26.44 .+-. 9.89 Tumor/Blood 1.34 .+-. 0.30 1.39 .+-.
0.26 3.07 .+-. 0.79 2.83 .+-. 0.81 Tumor/Large Intestine 26.88 .+-.
12.11 11.65 .+-. 2.99 33.67 .+-. 8.82 28.86 .+-. 10.28 Tumor/Small
Intestine 6.42 .+-. 1.01 8.96 .+-. 1.71 19.37 .+-. 5.95 16.33 .+-.
5.12 Tumor/Kidney 1.83 .+-. 0.27 2.00 .+-. 0.53 3.61 .+-. 1.05 3.68
.+-. 1.10 Tumor/Muscle 14.92 .+-. 2.85 14.84 .+-. 3.69 45.12 .+-.
8.55 37.37 .+-. 16.06 Tumor/Bone 8.43 .+-. 2.07 16.15 .+-. 8.89
29.8 .+-. 8.38 25.46 .+-. 8.22
[0127] Table 12 shows biodistribution data for in vivo pretargeting
experiment using .sup.64Cu-Tz-SarAr and a 24 h accumulation
interval.
TABLE-US-00013 TABLE 12 1 h 4 h 12 h 24 h Blood 4.20 .+-.
0.80.sup.a 4.00 .+-. 0.37 2.19 .+-. 0.39 2.61 .+-. 0.20 Tumor 5.63
.+-. 0.67 5.56 .+-. 0.91 6.74 .+-. 1.26 7.38 .+-. 2.02 Heart 1.81
.+-. 0.46 1.45 .+-. 0.03 0.84 .+-. 0.10 0.81 .+-. 0.04 Lung 1.65
.+-. 0.51 1.55 .+-. 0.45 1.24 .+-. 0.22 0.99 .+-. 0.24 Liver 1.60
.+-. 0.12 1.45 .+-. 0.21 1.33 .+-. 0.53 1.51 .+-. 0.20 Spleen 0.98
.+-. 0.25 0.81 .+-. 0.20 0.65 .+-. 0.17 0.64 .+-. 0.04 Stomach 0.73
.+-. 0.19 0.56 .+-. 0.20 0.21 .+-. 0.10 0.28 .+-. 0.07 Large
Intestine 0.21 .+-. 0.09 0.48 .+-. 0.09 0.20 .+-. 0.04 0.26 .+-.
0.06 Small Intestine 0.88 .+-. 0.09 0.62 .+-. 0.06 0.35 .+-. 0.08
0.45 .+-. 0.07 Kidney 3.08 .+-. 0.28 2.77 .+-. 0.57 1.87 .+-. 0.42
2.00 .+-. 0.24 Muscle 0.38 .+-. 0.06 0.37 .+-. 0.07 0.15 .+-. 0.01
0.20 .+-. 0.07 Bone 0.67 .+-. 0.14 0.34 .+-. 0.18 0.23 .+-. 0.05
0.29 .+-. 0.05 .sup.aValues are % ID/g .+-. SD. Mice (n = 4)
bearing subcutaneous SW1222 xenografts were administered huA33-TCO
via tail vein injection. After 24 h, the same mice were
administered .sup.64Cu-Tz-SarAr, also via tail vein injection.
[0128] Moreover, the PET imaging and biodistribution data for both
designed systems outperformed the .sup.64Cu-Tz-NOTA system (FIG. 26
and Tables 13-14). First, the activity concentrations in the tumor
were higher using the .sup.64Cu-Tz-SarAr approach. For example,
.sup.64Cu-Tz-SarAr demonstrated an activity concentration of
5.56.+-.0.91% ID/g in the tumor whereas .sup.64Cu-Tz-NOTA
demonstrated an activity concentration of 4.09.+-.0.61% ID/g at the
same time-point of 4 h post-injection Second, the chelator
structure alteration disclosed herein achieved higher
tumor-to-background activity ratios compared to the
.sup.64Cu-Tz-NOTA radioligand. For example, at 12 h after
injection, the tumor-to-muscle and tumor-to-blood activity ratios
for .sup.64Cu-Tz-SarAr were 3.1.+-.0.8 and 45.1.+-.8.6,
respectively, compared to 1.8.+-.0.5 and 26.6.+-.6.6 for
.sup.64Cu-Tz-NOTA. Third, the clearance of the .sup.64Cu-Tz-SarAr
and .sup.64Cu-Tz-NOTA radiotracers through the GI tract differed.
For example, at 1 h post-injection, the activity concentration of
.sup.64Cu-Tz-NOTA in the large intestine and its contents was
13.29.+-.3.15% ID/g compared to an activity concentration of
0.21.+-.0.09% ID/g for .sup.64Cu-Tz-SarAr. This caused the
tumor-to-large intestine activity ratio to be 1.44.+-.0.72 for
.sup.64Cu-Tz-NOTA to 33.67.+-.8.82 for .sup.64Cu-Tz-SarAr at 12 h
post-injection However, the .sup.64Cu-Tz-SarAr system exhibited
higher activity concentrations in its clearance organs, the
kidneys. Still, the activity levels of .sup.64Cu-Tz-SarAr in the
kidneys were generally below activity levels of .sup.64Cu-Tz-NOTA
measured in the gut. It is important to note that low levels of
residual uptake in the kidneys will not significantly interfere
with clinical imaging of primary colorectal carcinoma unlike uptake
in the large intestine.
[0129] Table 13 shows the biodistribution of .sup.64Cu-Tz-NOTA with
a 24 h accumulation interval. Contents within the stomach, small
intestine, and large intestine were not removed for the
measurements. This data was originally published in JNM. Zeglis, B.
M. et al. "A pretargeted PET imaging strategy based on
bioorthogonal Diels-Alder click chemistry." Journal of Nuclear
Medicine. 54, 1389-1396 (2013). .COPYRGT.2013 by the Society of
Nuclear Medicine and Molecular Imaging, Inc.
TABLE-US-00014 TABLE 13 1 h 4 h 12 h 24 h Blood 3.47 .+-. 0.63 2.61
.+-. 0.83 2.31 .+-. 0.4 2.07 .+-. 0.49 Tumor 4.07 .+-. 0.25 4.09
.+-. 0.61 4.20 .+-. 0.84 3.94 .+-. 0.92 Heart 1.09 .+-. 0.18 0.91
.+-. 0.27 0.92 .+-. 0.14 0.82 .+-. 0.21 Lung 1.58 .+-. 0.46 1.6
.+-. 0.39 1.09 .+-. 0.38 1.03 .+-. 0.31 Liver 2.19 .+-. 0.25 1.26
.+-. 0.3 0.93 .+-. 0.23 1.07 .+-. 0.15 Spleen 0.63 .+-. 0.07 0.51
.+-. 0.22 0.59 .+-. 0.25 0.45 .+-. 0.11 Stomach 0.45 .+-. 0.08 0.25
.+-. 0.12 0.52 .+-. 0.64 0.16 .+-. 0.03 Large 13.29 .+-. 3.15 9.43
.+-. 4.22 2.92 .+-. 1.34 1.67 .+-. 0.88 Intestine Blood 3.47 .+-.
0.63 2.61 .+-. 0.83 2.31 .+-. 0.4 2.07 .+-. 0.49 Small 0.03 .+-.
0.04 0.38 .+-. 0.08 0.77 .+-. 0.51 0.35 .+-. 0.04 Intestine Kidney
1.3 .+-. 0.15 0.95 .+-. 0.31 0.91 .+-. 0.29 0.7 .+-. 0.19 Muscle
0.22 .+-. 0.04 0.14 .+-. 0.03 0.16 .+-. 0.02 0.15 .+-. 0.02 Bone
0.3 .+-. 0.16 0.27 .+-. 0.24 0.35 .+-. 0.11 0.29 .+-. 0.07
[0130] Table 14 shows tumor-to-tissue activity concentration ratios
of .sup.64Cu-Tz-NOTA pretargeting experiment with a 24 h
accumulation interval. This data was originally published in JNM.
Zeglis, B. M. et al. "A pretargeted PET imaging strategy based on
bioorthogonal Diels-Alder click chemistry." Journal of Nuclear
Medicine. 54, 1389-1396 (2013). .COPYRGT.2013 by the Society of
Nuclear Medicine and Molecular Imaging, Inc.
TABLE-US-00015 TABLE 14 1 h 4 h 12 h 24 h Tumor/Blood 1.17 .+-.
0.22 1.57 .+-. 0.55 1.82 .+-. 0.48 1.9 .+-. 0.63 Tumor/Heart 3.75
.+-. 0.65 4.51 .+-. 1.49 4.58 .+-. 1.16 4.82 .+-. 1.69 Tumor/Lung
2.57 .+-. 0.76 2.55 .+-. 0.73 3.87 .+-. 1.55 3.83 .+-. 1.45
Tumor/Liver 1.86 .+-. 0.24 3.23 .+-. 0.9 4.53 .+-. 1.45 3.69 .+-.
1.01 Tumor/Spleen 6.46 .+-. 0.81 7.97 .+-. 3.57 7.1 .+-. 3.34 8.79
.+-. 2.98 Tumor/Stomach 8.96 .+-. 1.7 16.17 .+-. 8.21 8.12 .+-.
10.12 24.29 .+-. 6.89 Tumor/Large Intestine 0.31 .+-. 0.08 0.43
.+-. 0.2 1.44 .+-. 0.72 2.36 .+-. 1.37 Tumor/Small Intestine 119.52
.+-. 148.82 10.83 .+-. 2.8 5.46 .+-. 3.81 11.4 .+-. 2.91
Tumor/Kidney 3.14 .+-. 0.41 4.32 .+-. 1.56 4.6 .+-. 1.71 5.61 .+-.
1.98 Tumor/Muscle 18.42 .+-. 3.71 29.38 .+-. 8.5 26.63 .+-. 6.59
26.98 .+-. 7.41 Tumor/Bone 13.72 .+-. 7.63 14.95 .+-. 13.2 11.98
.+-. 4.51 13.43 .+-. 4.5
[0131] With a 24 h accumulation interval, the activity
concentration of .sup.64Cu-Tz-SarAr in the tumor reached a
relatively high 5.63.+-.0.67% ID/g at 1 h post-injection This value
increased slightly over the course of the experiment to
6.74.+-.1.26% ID/g at 12 h and 7.38.+-.2.02% ID/g at 24 h. These
data, combined with the relatively high blood activity values,
suggested that while the majority of the in vivo ligations occurred
at the tumor, some radioligands clicked with the antibody in the
blood and reached the tumor thereafter. Therefore, in an attempt to
decrease the frequency of click reactions in the blood and reduce
non-target tissue activity concentrations, PET imaging and
biodistribution experiments were conducted using longer
accumulation intervals of 48 and 120 h (FIGS. 18A-18B and FIGS.
19-24 and Tables 15-22).
[0132] Table 15 shows the biodistribution of .sup.64Cu-Tz-SarAr
pretargeting experiment with a 48 h accumulation interval. Female
athymic nude mice bearing subcutaneous SW1222 (right shoulder)
xenografts (100-150 mm.sup.3, 18-21 days post-inoculation) were
administered 100 .mu.g (0.66 nmol) huA33-TCO (in 200 .mu.L 0.9%
sterile saline) via intravenous tail vein injection. After an
accumulation interval of 48 h, the same mice were then administered
.sup.64Cu-Tz-SarAr (300-350 .mu.Ci in 200 .mu.L 0.9% sterile
saline) via intravenous tail vein injection (t=0). The specific
activity of the radiotracer was adjusted using cold
.sup.natCu-Tz-SarAr such that the molar ratio of
Tz.sub.injected:huA33.sub.injected=1:1. Animals (n=4 per group)
were euthanized by CO.sub.2(g) asphyxiation at 1, 4, 12, and 24 h
after injection. After asphyxiation, tissues were removed, rinsed
in water, dried in air for 5 min, weighed, and counted in a gamma
counter calibrated for .sup.64Cu. Counts were converted into
activity using a calibration curve generated from known standards.
Count data were background- and decay-corrected to the time of
injection, and the percent injected dose per gram (% ID/g) for each
tissue sample was calculated by normalization to the total activity
injected. Contents within the stomach, small intestine, and large
intestine were not removed for the measurements.
TABLE-US-00016 TABLE 15 1 h 4 h 12 h 24 h Blood 2.15 .+-. 0.5 1.78
.+-. 0.28 1.81 .+-. 0.54 0.92 .+-. 0.31 Tumor 4.49 .+-. 0.44 5.15
.+-. 1.42 4.94 .+-. 1.12 4.85 .+-. 0.67 Heart 1.05 .+-. 0.24 1.08
.+-. 0.32 0.88 .+-. 0.33 0.45 .+-. 0.08 Lung 1.68 .+-. 0.09 1.53
.+-. 0.28 1.00 .+-. 0.18 1.05 .+-. 0.51 Liver 1.79 .+-. 0.09 1.27
.+-. 0.19 1.08 .+-. 0.32 1.28 .+-. 0.33 Spleen 0.84 .+-. 0.27 0.6
.+-. 0.09 0.56 .+-. 0.11 0.5 .+-. 0.1 Stomach 0.39 .+-. 0.17 0.27
.+-. 0.18 0.12 .+-. 0.04 0.15 .+-. 0.03 Large Intestine 0.29 .+-.
0.09 0.41 .+-. 0.11 0.22 .+-. 0.08 0.16 .+-. 0.03 Blood 2.15 .+-.
0.5 1.78 .+-. 0.28 1.81 .+-. 0.54 0.92 .+-. 0.31 Small Intestine
0.54 .+-. 0.15 0.33 .+-. 0.1 0.3 .+-. 0.08 0.22 .+-. 0.07 Kidney
1.98 .+-. 0.26 1.83 .+-. 0.57 2.04 .+-. 0.36 1.47 .+-. 0.43 Muscle
0.22 .+-. 0.11 0.24 .+-. 0.08 0.15 .+-. 0.02 0.11 .+-. 0.04 Bone
0.23 .+-. 0.05 0.32 .+-. 0.12 0.3 .+-. 0.07 0.18 .+-. 0.05
[0133] Table 16 shows tumor-to-tissue activity concentration ratios
derived from the .sup.64Cu-Tz-SarAr pretargeting biodistribution
experiment with a 48 h accumulation interval as shown in Table
15.
TABLE-US-00017 TABLE 16 1 h 4 h 12 h 24 h Tumor/Blood 2.09 .+-.
0.52 2.9 .+-. 0.92 2.72 .+-. 1.03 5.27 .+-. 1.92 Tumor/Heart 4.27
.+-. 1.05 4.75 .+-. 1.92 5.62 .+-. 2.47 10.9 .+-. 2.55 Tumor/Lung
2.67 .+-. 0.3 3.37 .+-. 1.11 4.94 .+-. 1.45 4.61 .+-. 2.32
Tumor/Liver 2.51 .+-. 0.27 4.06 .+-. 1.27 4.58 .+-. 1.69 3.8 .+-.
1.11 Tumor/Spleen 5.34 .+-. 1.79 8.55 .+-. 2.69 8.75 .+-. 2.61 9.8
.+-. 2.47 Tumor/Stomach 11.57 .+-. 5.25 18.92 .+-. 13.29 41.88 .+-.
18.35 32.81 .+-. 8.37 Tumor/Large Intestine 15.48 .+-. 5.25 12.68
.+-. 4.87 22.66 .+-. 10.19 29.58 .+-. 6.11 Tumor/Small Intestine
8.35 .+-. 2.48 15.71 .+-. 6.48 16.47 .+-. 5.62 21.72 .+-. 7.59
Tumor/Kidney 2.27 .+-. 0.37 2.81 .+-. 1.16 2.42 .+-. 0.7 3.31 .+-.
1.07 Tumor/Muscle 20.34 .+-. 10.25 21.84 .+-. 9.2 33.88 .+-. 9.31
44.18 .+-. 17.61 Tumor/Bone 19.48 .+-. 4.94 15.86 .+-. 7.12 16.24
.+-. 5.16 26.55 .+-. 7.58
[0134] Table 17 shows the biodistribution of .sup.64Cu-Tz-SarAr
pretargeting experiment with a 120 h accumulation interval. Female
athymic nude mice bearing subcutaneous SW1222 (right shoulder)
xenografts (100-150 mm.sup.3, 18-21 days post-inoculation) were
administered 100 .mu.g (0.66 nmol) huA33-TCO (in 200 .mu.L 0.9%
sterile saline) via intravenous tail vein injection. After an
accumulation interval of 120 h, the same mice were then
administered .sup.64Cu-Tz-SarAr (300-350 .mu.Ci in 200 .mu.L 0.9%
sterile saline) via intravenous tail vein injection (t=0). The
specific activity of the radiotracer was adjusted using cold
.sup.natCu-Tz-SarAr such that the molar ratio of
Tz.sub.injected:huA33.sub.injected=1:1. Animals (n=4 per group)
were euthanized by CO.sub.2(g) asphyxiation at 1, 4, 12, and 24 h
after injection. After asphyxiation, tissues were removed, rinsed
in water, dried in air for 5 min, weighed, and counted in a gamma
counter calibrated for .sup.64Cu. Counts were converted into
activity using a calibration curve generated from known standards.
Count data were background- and decay-corrected to the time of
injection, and the percent injected dose per gram (% ID/g) for each
tissue sample was calculated by normalization to the total activity
injected. Contents within the stomach, small intestine, and large
intestine were not removed for the measurements.
TABLE-US-00018 TABLE 17 1 h 4 h 12 h 24 h Blood 1.39 .+-. 0.19 1.05
.+-. 0.29 0.44 .+-. 0.14 0.75 .+-. 0.23 Tumor 3.61 .+-. 0.45 3.55
.+-. 0.74 3.29 .+-. 0.40 4.34 .+-. 0.98 Heart 0.52 .+-. 0.06 0.43
.+-. 0.11 0.34 .+-. 0.20 0.40 .+-. 0.16 Lung 1.41 .+-. 0.21 0.91
.+-. 0.22 0.59 .+-. 0.27 0.85 .+-. 0.29 Liver 1.65 .+-. 0.07 1.16
.+-. 0.39 0.96 .+-. 0.09 1.06 .+-. 0.16 Spleen 0.60 .+-. 0.13 0.50
.+-. 0.05 0.34 .+-. 0.14 0.69 .+-. 0.17 Stomach 0.32 .+-. 0.13 0.25
.+-. 0.12 0.09 .+-. 0.03 0.15 .+-. 0.08 Large Intestine 0.29 .+-.
0.16 0.20 .+-. 0.13 0.09 .+-. 0.03 0.16 .+-. 0.04 Small Intestine
0.34 .+-. 0.03 0.22 .+-. 0.03 0.15 .+-. 0.07 0.17 .+-. 0.06 Kidney
1.80 .+-. 0.12 2.10 .+-. 0.20 2.11 .+-. 0.13 1.90 .+-. 0.17 Muscle
0.20 .+-. 0.03 0.11 .+-. 0.05 0.08 .+-. 0.04 0.14 .+-. 0.05 Bone
0.21 .+-. 0.03 0.16 .+-. 0.04 0.11 .+-. 0.04 0.25 .+-. 0.08
[0135] Table 18 shows tumor-to-tissue activity concentration ratios
derived from the .sup.64Cu-Tz-SarAr pretargeting biodistribution
experiment with a 120 h accumulation interval as shown in Table
17.
TABLE-US-00019 TABLE 18 1 h 4 h 12 h 24 h Tumor/Blood 2.61 .+-.
0.48 3.37 .+-. 1.16 7.46 .+-. 2.54 5.74 .+-. 2.17 Tumor/Heart 7.00
.+-. 1.22 8.24 .+-. 2.71 9.56 .+-. 5.64 10.76 .+-. 4.94 Tumor/Lung
2.55 .+-. 0.49 3.89 .+-. 1.23 5.55 .+-. 2.62 5.09 .+-. 2.06
Tumor/Liver 2.19 .+-. 0.29 3.06 .+-. 1.20 3.43 .+-. 0.52 4.09 .+-.
1.13 Tumor/Spleen 6.02 .+-. 1.46 7.03 .+-. 1.64 9.63 .+-. 4.03 6.26
.+-. 2.09 Tumor/Stomach 11.37 .+-. 4.88 14.04 .+-. 7.07 38.07 .+-.
12.42 29.21 .+-. 17.97 Tumor/Large Intestine 12.39 .+-. 7.14 17.82
.+-. 12.22 35.43 .+-. 12.17 26.48 .+-. 8.29 Tumor/Small Intestine
10.53 .+-. 1.58 16.22 .+-. 3.91 21.47 .+-. 9.60 25.34 .+-. 10.4
Tumor/Blood 2.61 .+-. 0.48 3.37 .+-. 1.16 7.46 .+-. 2.54 5.74 .+-.
2.17 Tumor/Kidney 2.01 .+-. 0.29 1.69 .+-. 0.39 1.56 .+-. 0.21 2.29
.+-. 0.56 Tumor/Muscle 18.41 .+-. 3.47 32.58 .+-. 16.17 38.74 .+-.
20.11 30.39 .+-. 11.94 Tumor/Bone 17.27 .+-. 3.03 21.53 .+-. 7.14
29.07 .+-. 11.14 17.16 .+-. 6.90
[0136] Table 19 shows a comparison of salient tumor-to-tissue
activity concentration ratios at 1 h post-injection created using
the different pretargeted PET imaging strategies discussed (see
Tables 11, 14, 16, and 18).
TABLE-US-00020 TABLE 19 Radioligand .sup.64Cu-Tz- NOTA
.sup.64Cu-Tz-SarAr Accumulation Interval 24 h 24 h 48 h 120 h
Tumor/Blood 1.17 .+-. 0.22 1.34 .+-. 0.3 2.09 .+-. 0.52 2.61 .+-.
0.48 Tumor/Liver 1.86 .+-. 0.24 3.52 .+-. 0.49 2.51 .+-. 0.27 2.19
.+-. 0.29 Tumor/Large Intestine 0.31 .+-. 0.08 26.88 .+-. 12.11
15.48 .+-. 5.25 12.39 .+-. 7.14 Tumor/Kidney 3.14 .+-. 0.41 1.83
.+-. 0.27 2.27 .+-. 0.37 2.01 .+-. 0.29 Tumor/Muscle 18.42 .+-.
3.71 14.92 .+-. 2.85 20.34 .+-. 10.25 18.41 .+-. 3.47
[0137] Table 20 shows a comparison of salient tumor-to-tissue
activity concentration ratios at 4 h post-injection created using
the different pretargeted PET imaging strategies discussed (see
Tables 11, 14, 16, and 18).
TABLE-US-00021 TABLE 20 Radioligand .sup.64Cu-Tz- NOTA
.sup.64Cu-Tz-SarAr Accumulation Interval 24 h 24 h 48 h 120 h
Tumor/Blood 1.57 .+-. 0.55 1.39 .+-. 0.26 2.9 .+-. 0.92 3.37 .+-.
1.16 Tumor/Liver 3.23 .+-. 0.9 3.83 .+-. 0.83 4.06 .+-. 1.27 3.06
.+-. 1.2 Tumor/Large Intestine 0.43 .+-. 0.2 11.65 .+-. 2.99 12.68
.+-. 4.87 17.82 .+-. 12.22 Tumor/Kidney 4.32 .+-. 1.56 2.00 .+-.
0.53 2.81 .+-. 1.16 1.69 .+-. 0.39 Tumor/Muscle 29.38 .+-. 8.5
14.84 .+-. 3.69 21.84 .+-. 9.2 32.58 .+-. 16.17
[0138] Table 21 shows a comparison of salient tumor-to-tissue
activity concentration ratios at 12 h post-injection created using
the different pretargeted PET imaging strategies discussed (see
Tables 11, 14, 16, and 18).
TABLE-US-00022 TABLE 21 Radioligand .sup.64Cu-Tz- NOTA
.sup.64Cu-Tz-SarAr Accumulation Interval 24 h 24 h 48 h 120 h
Tumor/Blood 1.82 .+-. 0.48 3.07 .+-. 0.79 2.72 .+-. 1.03 7.46 .+-.
2.54 Tumor/Liver 4.53 .+-. 1.45 5.06 .+-. 2.23 4.58 .+-. 1.69 3.43
.+-. 0.52 Tumor/Large Intestine 1.44 .+-. 0.72 33.67 .+-. 8.82
22.66 .+-. 10.19 35.43 .+-. 12.17 Tumor/Kidney 4.6 .+-. 1.71 3.61
.+-. 1.05 2.42 .+-. 0.7 1.56 .+-. 0.21 Tumor/Muscle 26.63 .+-. 6.59
45.12 .+-. 8.55 33.88 .+-. 9.31 38.74 .+-. 20.11
[0139] Table 22 shows a comparison of salient tumor-to-tissue
activity concentration ratios at 24 h post-injection created using
the different pretargeted PET imaging strategies discussed (see
Tables 11, 14, 16, and 18).
TABLE-US-00023 TABLE 22 Radioligand .sup.64Cu-Tz- NOTA
.sup.64Cu-Tz-SarAr Accumulation Interval 24 h 24 h 48 h 120 h
Tumor/Blood 1.9 .+-. 0.63 2.83 .+-. 0.81 5.27 .+-. 1.92 5.74 .+-.
2.17 Tumor/Liver 3.69 .+-. 1.01 4.87 .+-. 1.48 3.8 .+-. 1.11 4.09
.+-. 1.13 Tumor/Large Intestine 2.36 .+-. 1.37 28.86 .+-. 10.28
29.58 .+-. 6.11 26.48 .+-. 8.29 Tumor/Kidney 5.61 .+-. 1.98 3.68
.+-. 1.1 3.31 .+-. 1.07 2.29 .+-. 0.56 Tumor/Muscle 26.98 .+-. 7.41
37.37 .+-. 16.06 44.18 .+-. 17.61 30.39 .+-. 11.94
[0140] Two trends were observed. First, the activity concentrations
in the tumor were decreased using longer intervals. For example,
the activity concentrations decreased from 5.6.+-.0.9% ID/g at 4 h
post-injection using a 24 h interval to 5.2.+-.1.4% ID/g and
3.6.+-.0.7% ID/g at the same time-point using 48 and 120 h
intervals, respectively (FIG. 18C). It is thought that this is
because the TCO moiety is not infinitely stable to trans-cis
isomerization (and thus inactivation) in vivo. However, in both
cases the amount of uptake in the tumor at 1 h post-injection was
nearly identical to that at 24 h, suggesting that longer
accumulation intervals effectively eliminated click ligations in
the blood. Second, the activity concentrations in the blood and
most other tissues were reduced (FIG. 18D). The activity
concentration remaining in the blood at 4 h post-injection with a
24 h accumulation interval was 4.0.+-.0.37% ID/g. Using 48 and 120
h intervals, the corresponding values decreased to 1.78.+-.0.28%
ID/g and 1.05.+-.0.29% ID/g, respectively. Taken together, these
two trends resulted in higher tumor-to-blood activity ratios for
the longer accumulation intervals, for example, 2.83.+-.0.81,
5.27.+-.1.92, and 5.74.+-.2.17 at 24 h post-injection for 24, 48,
and 120 h intervals, respectively (FIG. 18E). Tumor-to-background
activity ratios remained lowed in non-target tissue because
activity concentrations were offset by the decreases in the
activity concentrations in the tumor (FIG. 18F).
Autoradiography and Immunohistochemistry
[0141] Immediately following the pretargeted PET imaging studies,
ex vivo autoradiographical and immunohistochemical analyses were
performed on the SW1222 xenografts in order to learn more about the
microscopic distribution of the huA33-TCO and .sup.64Cu-Tz-SarAr
(FIG. 25). As expected, hematoxylin and eosin staining of the
excised tumors revealed that both huA33-TCO and .sup.64Cu-Tz-SarAr
were almost exclusively associated with tumor cells rather than
regions of stromal tissue. Moreover, microscopic co-localization of
the autoradiographical signal of .sup.64Cu-Tz-SarAr and the
fluorescence staining for huA33-TCO was demonstrated. These
observations further supported the selective, in vivo formation of
the completed .sup.64Cu-SarAr huA33 radioimmunoconjugate.
Dosimetry
[0142] The radiation dosimetry of .sup.64Cu-Tz-SarAr was performed
to ensure the selective delivery of radioisotopes to malignant
tissues at radiation doses below the doses of traditional
radioimmunoconjugates. To this end, dosimetry calculations were
performed using the biodistribution data collected and the OLINDA
computer program to determine the mean organ absorbed doses
(rad/mCi) and effective dose (rem/mCi) for each strategy (Table
23). The total effective dose of the .sup.64Cu-Tz-SarAr
pretargeting strategy with a 24 h interval period was 0.041
rem/mCi, a slight reduction compared to the 0.046 rem/mCi effective
dose created by .sup.64Cu-Tz-NOTA. This difference was due to the
significant reduction in the mean organ absorbed dose to the large
intestine. Moreover, the total effective dose of the
.sup.64Cu-Tz-SarAr pretargeting strategy was inversely proportional
to the duration of the accumulation interval. For example, the
effective dose decreased from 0.041 rem/mCi with a 24 h interval to
0.038 rem/mCi with a 48 h interval to 0.034 with a 120 h
interval.
[0143] Table 23 shows dosimetry calculations for various
huA33-based PET imaging strategies.
TABLE-US-00024 TABLE 23 Pretargeting .sup.64Cu-Tz- .sup.89Zr-
.sup.64Cu- NOTA* .sup.64Cu-Tz-SarAr Target DFO NOTA 24 h 24 h 48 h
120 h Organ.sup..dagger. huA33* huA33* interval interval interval
interval Adrenals 1.64 0.0726 0.0251 0.0374 0.0348 0.0322 Brain
0.764 0.0555 0.0236 0.0361 0.0339 0.0316 Breasts 0.621 0.0509
0.0209 0.0323 0.0303 0.0281 Gallbladder 1.44 0.0741 0.0272 0.0391
0.0368 0.0341 Wall Lower Lg. 1.34 0.193 0.166 0.0482 0.0456 0.0400
Int. Wall Small 1.11 0.0832 0.033 0.0418 0.0390 0.0362 Intestine
Stomach 0.949 0.0883 0.0267 0.0552 0.0422 0.0394 Wall Upper Lg.
1.20 0.145 0.114 0.0409 0.0382 0.0355 Int. Wall Heart Wall 1.55
0.108 0.0294 0.0427 0.0379 0.0330 Kidneys 2.53 0.186 0.0315 0.0661
0.0539 0.0566 Liver 2.84 0.194 0.0311 0.0303 0.0334 0.0301 Lungs
2.26 0.179 0.0289 0.0325 0.0326 0.0216 Muscle 1.27 0.0546 0.0138
0.0193 0.0163 0.0139 Ovaries 1.09 0.0681 0.0299 0.0401 0.0374
0.0346 Pancreas 1.37 0.0708 0.0258 0.0395 0.0364 0.0338 Red Marrow
3.12 0.308 0.0530 0.0301 0.0280 0.0258 Osteogenic 6.09 0.439 0.0852
0.0893 0.0805 0.0720 Cells Skin 0.677 0.0464 0.0194 0.0297 0.0277
0.0258 Spleen 2.52 0.120 0.0180 0.0370 0.0205 0.0225 Adrenals 1.64
0.0726 0.0251 0.0374 0.0348 0.0322 Testes 0.683 0.0522 0.0225
0.0345 0.0322 0.0299 Thymus 0.988 0.0584 0.0227 0.0349 0.0325
0.0299 Thyroid 0.947 0.0563 0.0228 0.0351 0.0328 0.0303 Bladder
Wall 0.826 0.0609 0.0262 0.0391 0.0365 0.0338 Uterus 0.941 0.0652
0.0277 0.0410 0.0383 0.0355 Total Body 1.39 0.0855 0.0272 0.0379
0.0348 0.0316 Effective 1.54 0.133 0.046 0.0414 0.0377 0.0341 Dose
.sup..dagger.Mean organ absorbed doses and effective dose are
expressed in rad/mCi and rem/mCi, respectively. *Data originally
reported in Zeglis, B. M. et al. Journal of Nuclear Medicine. 54,
1389-1396 (2013). .COPYRGT.2013 by the Society of Nuclear Medicine
and Molecular Imaging, Inc.
[0144] Next, the dosimetry of the .sup.64Cu-Tz-SarAr pretargeting
strategy and directly labeled antibodies was compared. Using a 120
h accumulation interval, the .sup.64Cu-Tz-SarAr pretargeting
approach yielded an effective dose of 0.034 rem/mCi, a nearly
four-fold reduction compared to the 0.133 rem/mCi effective dose
delivered by huA33 labeled directly with .sup.64Cu. Moreover, the
effective doses of .sup.64Cu-Tz-SarAr to huA33 directly labeled
with .sup.89Zr was compared. In this case, the effective dose of
.sup.89Zr-DFO huA33 was 1.54 rem/mCi, or almost 50 times greater
than the 0.034 rem/mCi dose associated with .sup.64Cu-Tz-SarAr
pretargeting with a 120 h accumulation interval. In some tissues,
this dose rate reduction was more pronounced. For example, the mean
absorbed doses to osteogenic cells and red marrow with
.sup.89Zr-DFO huA33 was 6.09 rad/mCi and 3.12 rad/mCi,
respectively, approximately 80 and 120 times higher than the dose
delivered to the same tissues by the .sup.64Cu-Tz-SarAr
pretargeting approach.
Experimental Examples of .sup.64Cu Tetrazine Radioligands
Methods and Materials
[0145] Unless otherwise noted, all chemicals were acquired from
Sigma-Aldrich (St. Louis, Mo.) and were used as received without
further purification. All water employed was ultra-pure (greater
than 18.2 M.sup.-1 cm.sup.-1 at 25.degree. C.), all DMSO was of
molecular biology grade (greater than 99.9%), and all other
solvents were of the highest grade commercially available.
Acetonitrile (CH3CN) and dimethylformamide (DMF) were purchased
from Acros Organics (Waltham, Mass.) as extra dry over molecular
sieves. Amine-reactive trans-cyclooctene [(E)-cyclooct-4-enyl
2,5-dioxo-1-pyrrolidinyl carbonate; TCO-NHS)] and amine-reactive
tetrazine (2,6-dioxo-1-pyrrolidinyl
5-[4-(1,2,4,5-tetrazin-3-yl)benzylamino]-5-oxopentanoate; Tz-NHS)
were purchased from Sigma-Aldrich (St. Louis, Mo.). p-NCS-Bn-NOTA,
p-NH2-Bn-NOTA, and DiAmSar chelators were purchased from
Macrocyclics, Inc. (Dallas, Tex.). Tz-NOTA and 64Cu-Tz-NOTA were
synthesized as previously reported. 44 Humanized A33 (huA33)
antibody was generously provided by the Ludwig Institute for Cancer
Research (New York, N.Y.) and stored at -80.degree. C. prior to
use. .sup.64Cu was purchased from Washington University, St. Louis,
where it was produced on a medical cyclotron (Model CS-15,
Cyclotron Corp.) via the .sup.64Ni(p,n).sup.64Cu transformation and
purified as previously described to yield [.sup.64Cu]CuCl.sub.2
with an effective specific activity of 200-400 mCi/.mu.g. 45 Human
colorectal cancer cell line SW1222 was obtained from the Ludwig
Institute for Cancer Immunotherapy and grown by serial passage.
Amine-reactive AlexaFluor.RTM. 680 (AF680-NHS) was purchased from
ThermoFisher Scientific (Waltham, Mass.).
Synthesis of tert-butyl
(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-3,7-dioxo-11,14,17,20,23,26,29
heptaoxa-2,8-diazahentriacontan-31-yl)carbamate (Tz-PEG7-NHBoc)
[0146] Tz-NHS (10 mg; 0.025 mmol; 398.4 g/mol) was dissolved in 400
.mu.L DMSO and added to 15 mg
O-(2-aminoethyl)-O'-[2-(bocamino)ethyl]hexaethylene glycol (0.032
mmol; 1.3 equiv.; 468.6 g/mol). 10 .mu.L triethylamine (7.3 mg;
0.072 mmol; 101.2 g/mol) was then added to this solution, and the
solution was placed on an agitating thermomixer at 300 rpm for 30
minutes at room temperature. After 30 minutes, the reaction was
purified via preparative C18 HPLC using a gradient of 5:95 MeCN:H2O
(both with 0.1% TFA) to 95:5 MeCN:H2O over 30 min (tR=18.2 min).
Lyophilization of the HPLC eluent yielded the purified product as a
16 mg of a bright pink powder (MW=751.9 g/mol; 0.021 mmol; 85%
yield). 1H NMR (500 MHz, DMSO), .delta., ppm: 10.52 (s, 1H), 8.50
(m, 3H), 7.82 (t, 1H), 7.46 (d, 2H), 6.69 (t, 1H), 4.33 (d, 2H),
3.42 (m, 22H), 3.33 (t, 2H), 3.31 (t, 2H), 3.12 (q, 2H), 2.99 (q,
2H), 2.12 (t, 2H), 2.03 (t, 2H), 2.12 (t, 2H), 1.70 (q, 2H), 1.29
(s, 9H). ESI-MS(+): m/z (%)=753.1 [M+H]+ HRMS (ESI): m/z calcd. for
C35H57N7O11Na: 774.4005. found: 774.4014. UV-Vis:
.epsilon..sub.525=530 M.sup.-1 cm.sup.-1.
Synthesis of
N.sup.1-(4-(1,2,4,5-tetrazin-3-yl)benzyl)-N.sup.5-(23-amino-3,6,9,12,15,1-
8,21 heptaoxatricosyl)glutaramide (Tz-PEG.sub.7-NH.sub.2)
[0147] Tz-PEG.sub.7-NHBoc (10 mg; 0.014 mmol; 717.5 g/mol) was
dissolved in 400 .mu.L of 1:1 CH.sub.2Cl.sub.2:TFA and placed on an
agitating thermomixer at 300 rpm for 30 minutes at room
temperature. After 30 minutes, the solvent was removed via rotary
evaporation, the residue was taken back up in H.sub.2O, and the
reaction was purified via preparative C.sub.18 HPLC using a
gradient of 5:95 MeCN:H.sub.2O (both with 0.1% TFA) to 95:5
MeCN:H.sub.2O over 30 min (t.sub.R=12.5 min). Lyophilization of the
HPLC eluent yielded the purified product as 9 mg of a bright pink
powder (MW=651.7; 0.013 mmol; 95% yield). .sup.1H NMR (500 MHz,
DMSO), .delta., ppm: 10.58 (s, 1H), 8.46 (m, 2H), 7.87 (t, 1H),
7.75 (d, 2H), 7.52 (d, 1H), 4.40 (d, 2H), 3.60-3.50 (m, 26H), 3.40
(t, 2H), 3.32 (bs, 2H), 3.20 (q, 2H), 2.99 (bs, 2H), 2.19 (t, 2H),
2.12 (t, 2H), 1.79 (q, 2H). ESI-MS(+): m/z (%)=652.9 [M+H].sup.+
HRMS (ESI): m/z calcd. for C.sub.30H.sub.50N.sub.7O.sub.9:
652.3670. found: 652.3676. UV-Vis: .epsilon..sub.525=535 M.sup.-1
cm.sup.-1.
Synthesis of
2,2',2''-(2-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-3,7-dioxo-11,14,17-
,20,23,26,29
heptaoxa-2,8-diazahentriacontan-31-yl)thioureido)benzyl)-1,4,7-triazonane-
-1,4,7-triyl)triacetic acid (Tz-PEG.sub.7-NOTA)
[0148] Tz-PEG.sub.7-NH.sub.2 (5 mg; 0.008 mmol; 651.8 g/mol) was
dissolved in 400 .mu.L DMSO and added to 10 mg p-NCS-Bn-NOTA (0.022
mmol; 2.75 equiv.; 450.5 g/mol). 10 .mu.L triethylamine (7.3 mg;
0.072 mmol; 101.2 g/mol) was then added to this solution, and the
solution was placed on an agitating thermomixer at 300 rpm for 30
minutes at room temperature. After 30 minutes, the reaction was
purified via preparative C.sub.18 HPLC using a gradient of 5:95
MeCN:H.sub.2O (both with 0.1% TFA) to 95:5 MeCN:H.sub.2O over 30
min (t.sub.R=15.5 min). Lyophilization of the HPLC eluent yielded
the purified product as 6 mg of a bright pink powder (MW=1102.2;
0.005 mmol; 68% yield). .sup.1H NMR (500 MHz, DMSO), .delta., ppm:
10.51 (s, 1H), 9.50 (bs, 1H), 8.40 (m, 3H), 7.79 (m, 1H), 7.62 (m,
1H), 7.47 (d, 2H), 7.35 (d, 2H), 7.03 (d, 2H), 4.43 (d, 2H),
4.00-3.20 (m, 50H), 3.12 (q, 2H), 2.96 (bs, 2H), 2.11 (t, 2H), 2.03
(t, 2H), 1.70 (q, 2H). ESI-MS(-): m/z (%)=1100.6 [M-H].sup.-; 549.9
[M-2H].sup.2- HRMS (ESI): m/z calcd. for
C.sub.50H.sub.76N.sub.11O.sub.15S: 1102.5243. found: 1102.5253.
UV-Vis: .epsilon..sub.525=540 M.sup.-1 cm.sup.-1.
Synthesis of
N.sup.1-(4-(((pivaloyloxy)amino)methyl)benzyl)-3,6,10,13,16,19
exaazabicyclo[6.6.6]icosane-1,8-diamine (SarAr-Bn-NHBoc)
[0149] N-Boc-4-(bromomethyl)-benzylamine (0.037 g; 0.12 mmol; 1.3
equiv.; 300.2 g/mol) was added to a stirred solution of DiAmSar
(0.030 g; 0.094 mmol; 1.0 equiv.; 314.5 g/mol) in anhydrous
dimethylformamide (4.0 mL) at room temperature. Sodium carbonate
(0.034 g; 0.32 mmol; 3.5 equiv.; 105.9 g/mol) was added, and the
reaction solution was stirred at 70.degree. C. for 16 h. The
reaction was diluted with water (6.0 mL), and purification by HPLC
(3.0 mL/min, 5% to 80% CH.sub.3CN in 15 min) afforded
SarAr-Bn-NHBoc (MW=533.8; 0.035 g; 70%) as a colorless solid:
t.sub.R=9.4 min. .sup.1H NMR (500 MHz, DMSO), .delta., ppm:
7.38-7.50 (m, 4H), 4.18 (m, 2H), 2.31-3.98 (m, 42H), 1.35 (s, 9H).
ESI-MS(+): m/z=534.5 [M+H].sup.+. HRMS (ESI): m/z calcd. for
C.sub.27H.sub.52N.sub.9O.sub.2: 534.4244. found: 534.4250.
Synthesis of N.sup.1-(4-(aminomethyl)benzyl)-3,6,10,13,16,19
hexaazabicyclo[6.6.6]icosane-1,8-diamine (SarAr-Bn-NH.sub.2)
[0150] Trifluoroacetic acid (2.0 mL) was added slowly to a stirred
solution of SarAr-Bn-NHBoc (0.031 g; 0.058 mmol; 1.0 equiv.; 533.4
g/mol) in dry acetonitrile (2.0 mL), and the reaction mixture was
stirred at room temperature for 90 min. Evaporation of the solvents
under reduced pressure and purification by HPLC (6.0 mL/min, 5% to
60% CH.sub.3CN in 20 min) afforded SarAr-Bn-NH.sub.2 (MW=434.7;
0.026 g, 99%) as a colorless solid: t.sub.R=6.8 min. .sup.1H NMR
(500 MHz, DMSO), .delta., ppm: 7.55 (d, 2H), 7.51 (d, 2H), 4.23 (s,
2H), 2.56-4.05 (m, 27H). ESI-MS(+): m/z=434.4 [M+H].sup.+. HRMS
(ESI): m/z calcd. for C.sub.22H.sub.44N.sub.9: 434.3720. found:
434.3715.
Synthesis of
N.sup.1-(4-(1,2,4,5-tetrazin-3-yl)benzyl)-N.sup.5-(4-(((8-amino-3,6,10,13-
,16,19
hexaazabicyclo[6.6.6]icosan-1-yl)amino)methyl)benzyl)glutaramide
(Tz-SarAr)
[0151] A solution of Tz-NHS (5.0 mg; 0.013 mmol; 1.0 equiv.; 398.4
g/mol) in anhydrous dimethylformamide (400 .mu.L) was added to a
stirred solution of SarAr-Bn-NH.sub.2 (5.4 mg; 0.013 mmol; 1.0
equiv.; 434.7 g/mol) in anhydrous dimethylformamide (200 .mu.L) at
room temperature, and the reaction solution was stirred in the dark
for 2 h at room temperature. After dilution with water (1.8 mL),
purification by HPLC (1.0 mL/min, 5% to 80% CH.sub.3CN in 15 min)
afforded Tz-SarAr (MW=716.9; 3.9 mg; 42%) as a pink solid:
t.sub.R=9.5 min. .sup.1H NMR (600 MHz, D.sub.2O), .delta., ppm:
10.25 (s, 1H), 8.31 (d, 2H), 7.46 (d, 2H), 7.22-7.27 (m, 4H), 4.39
(m, 2H), 4.24 (m, 3H), 2.46-3.95 (m, 24H), 2.41-2.44 (m, 4H), 1.83
(m, 2H). ESI-MS(+): m/z=717.6 [M+H].sup.+. HRMS (ESI): m/z calcd.
for C.sub.36H.sub.57N.sub.14O.sub.2: 717.4789. found: 717.4788.
Preparation of .sup.64 Cu-Tz-PEG.sub.7-NOTA
[0152] A solution of Tz-PEG.sub.7-NOTA (5-25 .mu.g; 4.5-22.6 nmol)
in NH.sub.4OAc buffer (0.2 M, pH 5.5, 200 .mu.L) was first
prepared. Then, the desired amount of .sup.64CuCl.sub.2 in 0.1 M
HCl (1500-7500 .mu.Ci) was added to the reaction mixture, and the
solution was placed on an agitating thermomixer at 300 rpm for 30
minutes at room temperature. After this incubation, the
.sup.64Cu-Tz-PEG.sub.7-NOTA was purified via reverse phase C.sub.18
HPLC (t.sub.R=9.7 min) to yield the completed radioligand in
greater than 99% radionuclidic purity, 78.+-.6% decay-corrected
isolated yield, and a specific activity of 278.+-.32 .mu.Ci/.mu.g
(323.+-.37 mCi/.mu.mol).
Preparation of .sup.64 Cu-Tz-SarAr
[0153] A solution of Tz-SarAr (5-25 .mu.g; 6.9-34.9 nmol) in
NH.sub.4OAc buffer (0.2 M, pH 5.5, 200 .mu.t) was first prepared.
Then, the desired amount of .sup.64CuCl.sub.2 in 0.1 M HCl
(1500-7500 .mu.Ci) was added to the reaction mixture, and the
solution was placed on an agitating thermomixer at 300 rpm for 30
minutes at room temperature. After this incubation, the
.sup.64Cu-Tz-PEG.sub.7-NOTA was purified via reverse phase C.sub.18
HPLC (t.sub.R=8.7 min) to yield the completed radioligand in
greater than 99% radionuclidic purity, 79.+-.7% decay-corrected
isolated yield, and a specific activity of 398.+-.46 .mu.Ci/.mu.g
(310.+-.36 mCi/.mu.mol) (n=6).
Pretargeted PET Imaging Experiments
[0154] All pretargeted PET imaging experiments were performed on an
Inveon PET/CT scanner (Siemens Healthcare Global). Female athymic
nude mice (n=5 per radioligand) bearing subcutaneous SW1222 (right
shoulder) xenografts (100-150 mm.sup.3, 9-12 days post-inoculation)
were administered 100 .mu.g (0.66 nmol) huA33-TCO (in 200 .mu.L
0.9% sterile saline) via intravenous tail vein injection. After an
accumulation interval of 24, 48, or 120 h, the same mice were then
administered either .sup.64Cu-Tz-PEG.sub.7-NOTA or
.sup.64Cu-Tz-SarAr (400-450 .mu.Ci in 200 .mu.L 0.9% sterile
saline), also via intravenous tail vein injection (t=0). For both
.sup.64Cu-Tz-PEG.sub.7-NOTA and .sup.64Cu-Tz-SarAr, the specific
activity of the radiotracer was adjusted using cold
.sup.natCu-Tz-PEG.sub.7-NOTA or .sup.natCu-Tz-SarAr such that the
molar ratio of Tz.sub.injected:huA33.sub.injected.apprxeq.1:1.
Approximately 5 minutes prior to the PET images, mice were
anesthetized by inhalation of 2% isoflurane (Baxter Healthcare,
Deerfield, Ill.)/oxygen gas mixture and placed on the scanner bed;
anesthesia was maintained using 1% isoflurane/gas mixture. Static
scans were recorded at various time points after injection with a
minimum of 30 million coincident events (10-30 min total scan
time). An energy window of 350-700 keV and a coincidence timing
window of 6 ns were used. Data were sorted into 2-dimensional
histograms by Fourier re-binning, and the images were reconstructed
using a two-dimensional ordered subset expectation maximization
(2DOSEM) algorithm (16 subsets, 4 iterations) into a
128.times.128.times.159 (0.78.times.0.78.times.0.80 mm) matrix. The
image data was normalized to correct for non-uniformity of response
of the PET, dead-time count losses, positron branching ratio, and
physical decay to the time of injection, but no attenuation,
scatter, or partial-volume averaging correction was applied.
Activity concentrations (percentage of dose per gram of tissue [%
ID/g]) and maximum intensity projections were determined by
conversion of the counting rates from the reconstructed images. All
of the resulting PET images were analyzed using ASIPro VM.TM.
software. Whole-body CT scans were acquired with a voltage of 80 kV
and 500 .mu.A. 120 rotational steps for a total of 220.degree. were
acquired with a total scan time of 120 s and 145 ms per frame
exposure. Combined PET/CT images were processed using Inveon
Research Workplace software.
Pretargeted Biodistribution Experiments
[0155] Female athymic nude mice bearing subcutaneous SW1222 (right
shoulder) xenografts (100-150 mm.sup.3, 9-12 days post-inoculation)
were administered 100 .mu.g (0.66 nmol) huA33-TCO (in 200 .mu.L
0.9% sterile saline) via intravenous tail vein injection. After an
accumulation interval period of 24, 48, or 120 h, the same mice
were then administered .sup.64Cu-Tz-SarAr (300-350 .mu.Ci in 200
.mu.L 0.9% sterile saline), also via intravenous tail vein
injection (t=0). As in the PET imaging experiments, the specific
activity of the radiotracer was adjusted using cold
.sup.natCu-Tz-SarAr such that the molar ratio of
Tz.sub.injected:huA33.sub.injected=1:1. Animals (n=4 per group)
were euthanized by CO.sub.2(g) asphyxiation at 1, 4, and 24 h after
injection. After asphyxiation, tissues were removed, rinsed in
water, dried in air for 5 min, weighed, and counted in a gamma
counter calibrated for .sup.64Cu. Counts were converted into
activity using a calibration curve generated from known standards.
Count data were background- and decay-corrected to the time of
injection, and the percent injected dose per gram (% ID/g) for each
tissue sample was calculated by normalization to the total activity
injected.
Instrumentation
[0156] All instruments were calibrated and maintained in accordance
with standard quality-control procedures. UV-Vis measurements were
taken on a Thermo Scientific NanoDrop 2000 Spectrophotometer. NMR
spectroscopy was performed on a Bruker 500 MHz NMR with TopSpin 2.1
software for spectrum analysis. Electrospray ionization mass
spectrometry (ESI-MS) spectra were recorded with a Waters Acquity
UPLC (Milford, Calif.) with electrospray ionization SQ detector.
High-resolution mass spectrometry (HRMS) spectra were recorded with
a Waters LCT Premier system (ESI). Activity measurements were made
using a Capintec CRC-15R Dose Calibrator (Capintec, Ramsey, N.J.).
For accurate quantification of activities, experimental samples
were counted for 1 min on a calibrated Perkin Elmer (Waltham,
Mass.) Automatic Wizard Gamma Counter. Labeling of antibodies with
.sup.64Cu-labeled tetrazine radioligands was monitored using
silica-gel impregnated glass-fiber instant thin-layer
chromatography paper (Pall Corp., East Hills, N.Y.) and analyzed on
a Bioscan AR-2000 radio-TLC plate reader using Winscan Radio-TLC
software (Bioscan Inc., Washington, D.C.).
HPLC
[0157] All HPLC purifications (6.0 mL/min, Buffer A: 0.1% TFA in
water, Buffer B: 0.1% TFA in CH.sub.3CN) were performed on a
Shimadzu UFLC HPLC system equipped with a DGU-20A degasser, a
SPD-M20A UV detector, a LC-6AB pump system, a CBM-20A communication
BUS module, and a FRC-10A fraction collector using a C.sub.18
reversed phase XTerra.RTM. Preparative MS OBD.TM. column (10 .mu.m,
19.2 mm.times.250 mm) or a C.sub.18 reversed phase semi-Prep
Phenomenex.RTM. Jupiter column (5 .mu.m, 10 mm.times.250 mm).
Quality controls of synthesized compounds were performed using a
C.sub.18 reversed phase Atlantis.RTM. T3 column (5 .mu.m, 4.6
mm.times.250 mm). All radio-HPLC analysis and purification
experiments were performed using a Shimadzu HPLC equipped with a
C.sub.18 reversed phase column (Phenomenex Luna analytical
4.6.times.250 mm), 2 LC-10AT pumps, a SPD-M10AVP photodiode array
detector, a Bioscan Flow Counts radioactivity detector, and a
gradient of 5:95 CH.sub.3CN:H.sub.2O (both with 0.1% TFA) to 95:5
CH.sub.3CN:H.sub.2O over 15 min.
Synthesis of Tz-PEG.sub.7-AF680
[0158] Tz-PEG.sub.7-NH.sub.2 (1 mg; 0.0015 mmol; 651.8 g/mol) was
dissolved in 400 .mu.L DMSO and added to 2 mg AF680-NHS (0.0017
mmol; 1.1 equiv.; .about.1150 g/mol). 10 .mu.L triethylamine (7.3
mg; 0.072 mmol; 101.2 g/mol) was then added to this solution, and
the solution was placed on an agitating thermomixer at 300 rpm for
30 minutes at room temperature. After 30 minutes, the reaction was
purified via preparative C.sub.18 HPLC using a gradient of 5:95
CH.sub.3CN:H.sub.2O (both with 0.1% TFA) to 95:5
CH.sub.3CN:H.sub.2O over 30 min (t.sub.R=11.2 min). Lyophilization
of the HPLC eluent yielded the purified product as a 2 mg of a
bright orange powder (MW .about.1750; .about.0.0011 mmol;
.about.75% yield).
Preparation of huA33-TCO
[0159] huA33 (2 mg, 13.3 nmol) was dissolved in 500 .mu.L of
phosphate buffered saline (PBS, pH 7.4), and the pH of the solution
was adjusted to 8.8-9.0 with NaHCO.sub.3 (0.1 M). To this solution
was added an appropriate volume of TCO-NHS in DMF (10 mg/mL) to
yield a TCO-NHS:huA33 reaction stoichiometry of 10:1. The resulting
solution was incubated with gentle shaking for 30 min at room
temperature. After 30 min, the modified antibody was purified using
size-exclusion chromatography (Sephadex G-25 M, PD-10 column, GE
Healthcare; dead volume=2.5 mL, eluted with 500 mL fractions of
PBS, pH 7.4) and concentrated with centrifugal filtration units
with a 50,000 molecular weight cut off (Amicon.TM. Ultra 4,
Millipore Corp., Billerica, Mass.) and PBS (pH 7.4).
Determination of the TCO Occupancy of huA33-TCO
[0160] A solution of huA33-TCO (100 .mu.g; 0.66 nmol) in 900 .mu.L
PBS (pH 7.4) was first prepared (0.74 .mu.M). To this solution, 100
.mu.L of a 1 mM solution of Tz-PEG.sub.7-AF680 in DMSO was added to
create a reaction solution of 1000 .mu.L and concentrations of 0.66
.mu.M huA33-TCO and 100 .mu.M Tz-PEG.sub.7-AF680 (a .about.150 fold
excess of Tz). This solution was placed on an agitating thermomixer
at 300 rpm for 180 minutes at room temperature. After incubation,
the resulting fluorophore-labeled immunoconjugate was purified
using size-exclusion chromatography (Sephadex G-25 M, PD-10 column,
GE Healthcare; dead volume=2.5 mL, eluted with 500 mL fractions of
PBS, pH 7.4) and concentrated with centrifugal filtration units
with a 50,000 molecular weight cut off (Amicon.TM. Ultra 4,
Millipore Corp., Billerica, Mass.) and PBS (pH 7.4). The degree of
labeling (DOL) was determined via UV-Vis. Absorbance measurements
were taken at 280 nm and 680 nm for three separate antibody
concentrations. The DOL was calculated using the following
formulas:
A.sub.mAb=A.sub.280-A.sub.max(CF)
DOL=[A.sub.max*MW.sub.mAb]/[[mAb]*.epsilon..sub.AF680]
where the correction factor (CF) for AF680 was given as 0.05 by the
supplier, MW.sub.huA33=150,000, .epsilon..sub.AF680=184,000, and
.epsilon..sub.280, mAb=225,000. Given the rapid and quantitative
nature of the IEDDA reaction, the degree of labeling of AF680 was
assumed to be the degree of labeling of TCO.
Determination of Partition Coefficient
[0161] .sup.64Cu-Tz-PEG.sub.7-NOTA, .sup.64Cu-Tz-NOTA, or
.sup.64Cu-Tz-SarAr (1 .mu.Ci) was added to a mixture of 3 mL PBS
(pH 7.4) and 3 mL 1-octanol. The resulting mixture was then
vortexed thoroughly for 10 minutes and subsequently centrifuged at
1,000 rpm for 10 min. 1 mL of each layer (PBS and 1-octanol) was
then collected, and the amount of radioactivity in each sample was
counted on a gamma counter calibrated for .sup.64Cu. The partition
coefficient (log D) was calculated using the formula:
Log D=log.sub.10 [(counts.sub.octanol)/(counts.sub.PBS]
All experiments were performed in triplicate. Reaction of .sup.64
Cu-Tz Radioligands with huA33-TCO
[0162] In order to check their reactivity with TCO,
.sup.64Cu-Tz-PEG.sub.7-NOTA and .sup.64Cu-Tz-SarAr were added to a
solution of huA33 in PBS (500 .mu.L, pH 7.4) at a molar ratio of
Tz:mAb of 1:1. The resulting solution was placed on an agitating
thermomixer at 300 rpm for 30 minutes at room temperature. After
this incubation, the progress of the reaction was assayed using
radio-TLC with reverse-phase C.sub.18 TLC plates and a mobile phase
of 1:1 CH.sub.3CN:water (each with 0.1% TFA). Under these
conditions, the .sup.64Cu-labeled antibody will remain at the
baseline, while the .sup.64Cu-Tz-labeled radioligands will travel
up the plate. If the purified radioimmunoconjugate is desired, the
.sup.64Cu-Tz huA33 was then purified using size-exclusion
chromatography (Sephadex G-25 M, PD-10 column, GE Healthcare; dead
volume=2.5 mL, eluted with 500 mL fractions of PBS, pH 7.4).
Typically, crude radiochemical yields of 90-95% were obtained, and
post-purification radiochemical purities were greater than 99%
(corresponding to specific activities of 2.0-2.5 mCi/mg). All
experiments were performed in triplicate.
PBS and Serum Stability of .sup.64Cu-Tz-PEG.sub.7-NOTA and
.sup.64Cu-Tz-SarAr
[0163] .sup.64Cu-Tz-PEG.sub.7-NOTA and .sup.64Cu-Tz-SarAr (1000
.mu.Ci) were incubated on an agitating thermomixer (300 rpm) at
37.degree. C. in 500 .mu.L of either PBS (pH 7.4) or human serum.
At each prescribed time-point, 100 .mu.L of the solution was
removed and placed into a 1.7 mL microcentrifuge tube. For the PBS
samples, the compound was injected directly onto the HPLC and
analyzed using a gradient of 5:95 CH.sub.3CN:H.sub.2O (both with
0.1% TFA) to 95:5 CH.sub.3CN:H.sub.2O over 15 min. For the serum
samples, 100 .mu.L cold CH.sub.3CN was added to the serum, and the
resultant mixture was vortexed and centrifuged at 10,000 rpm for 10
min. After this, the clear supernatant was removed, moved to a new
1.7 mL microcentrifuge tube, and centrifuged again at 10,000 rpm
for 10 min. The clear supernatant from this second spin was then
injected into the HPLC and analyzed using a gradient of 5:95
CH.sub.3CN:H.sub.2O (both with 0.1% TFA) to 95:5
CH.sub.3CN:H.sub.2O over 15 min. The residual protein from the
centrifuge spins was checked for radioactivity, and only minimal
residual activity remained (less than 1% of the starting Cu for
each .sup.64Cu-Tz-PEG.sub.7-NOTA and .sup.64Cu-Tz-SarAr). The
fraction of intact .sup.64Cu-Tz-PEG.sub.7-NOTA or
.sup.64Cu-Tz-SarAr was determined by integrating the peak
corresponding to the compound (t.sub.R=9.7 and 8.7 minutes,
respectively) and dividing by the integral over the whole HPLC run.
Both the injection loop and column were monitored to detect the
presence of residual activity. All experiments were performed in
triplicate.
In Vivo Stability of .sup.64Cu-Tz-SarAr
[0164] Healthy athymic nude mice were injected with
.sup.64Cu-Tz-SarAr (300-350 .mu.Ci) via intravenous tail vein
injection. After 15 min, 1 h, or 4 h, the mice were sacrificed via
CO.sub.2 asphyxiation, and their blood (500 .mu.L) was collected
via cardiac puncture in heparinized 1.7 mL microcentrifuge tubes.
These tubes were then centrifuged at 10,000 rpm for 10 minutes to
separate plasma from red-blood cells. After 10 minutes, the plasma
supernatant was then transferred to a new 1.7 mL microcentrifuge
tube and placed on ice. Subsequently, 500 .mu.L of ice-cold
CH.sub.3CN was added to the plasma to precipitate the proteins, and
the tubes were vortexed briefly and centrifuged again for 10 min at
10,000 rpm. After this centrifugation, the supernatant was
carefully removed and transferred to another 1.7 mL microcentrifuge
tube, in which it was subjected to another round of centrifugation
at 10,000 rpm for 10 min. After this final centrifugation, the
supernatant was again transferred to a clean 1.7 mL microcentrifuge
tube. This solution was then analyzed via radio-TLC methods using
reverse-phase C.sub.18 TLC plates and a mobile phase of 1:1
CH.sub.3CN:water (each with 0.1% TFA). Using this method, any free
.sup.64Cu.sup.2+ will remain at the baseline, while
.sup.64Cu-Tz-SarAr and other metabolites will travel up the TLC
plate. The fraction of intact .sup.64Cu-Tz-SarAr was calculated by
dividing the integral of the parent compound peak over the integral
of the entire radio-TLC chromatogram. All experiments were
performed in triplicate.
Cell Culture
[0165] Human colorectal cell line SW1222 was obtained from the
Ludwig Institute of Cancer Research and maintained in Iscove's
Modified Dulbecco's Medium, supplemented with 10% heat-inactivated
fetal calf serum, 2.0 mM glutamine, 100 units/mL penicillin, and
100 units/mL streptomycin in a 37.degree. C. environment containing
5% CO.sub.2. Cell lines were harvested and passaged weekly using a
formulation 0.25% trypsin/0.53 mM EDTA in Hank's Buffered Salt
Solution without calcium and magnesium.
Xenograft Models
[0166] All animal experiments we performed under an Institutional
Animal Care and Use Committee-approved protocol, and the
experiments followed institutional guidelines for the proper and
humane use of animals in research. Six to eight week-old athymic
nude female mice were obtained from Charles River Laboratories
(Wilmington, Mass.). Animals were housed in ventilated cages, were
given food and water ad libitum, and were allowed to acclimatize
for approximately 1 week prior to inoculation. SW1222 tumors were
induced on the right shoulder by a subcutaneous injection of
5.0.times.10.sup.6 cells in a 150 .mu.L cell suspension of a 1:1
mixture of fresh media:BD Matrigel (BD Biosciences, Bedford, Ma).
The xenografts reached ideal size for imaging and biodistribution
(.about.100-150 mm.sup.3) in approximately 18-21 days.
Immunoreactivity Assays
[0167] Immunoreactivity assays employing the huA33-TCO antibodies
labeled with the .sup.64Cu-Tz radioligands were performed as
previously reported using A33 antigen-expressing SW1222 human
colorectal cancer cells. All experiments were performed in
triplicate.
PET Imaging with .sup.64 Cu-Labeled Tetrazine Radioligands
[0168] All PET imaging experiments were performed on an Inveon
PET/CT scanner (Siemens Healthcare Global). Healthy female athymic
nude mice (n=4 per radioligand) were administered
.sup.64Cu-Tz-NOTA, .sup.64Cu-Tz-PEG.sub.7-NOTA, or
.sup.64Cu-Tz-SarAr (300-350 .mu.Ci in 200 .mu.L 0.9% sterile
saline) via intravenous tail vein injection (t=0). Approximately 5
minutes prior to the PET images, mice were anesthetized by
inhalation of 2% isoflurane (Baxter Healthcare, Deerfield,
Ill.)/oxygen gas mixture and placed on the scanner bed; anesthesia
was maintained using 1% isoflurane/gas mixture. Static scans were
recorded at various time points after injection with a minimum of
30 million coincident events (10-30 min total scan time). An energy
window of 350-700 keV and a coincidence timing window of 6 ns were
used. Data were sorted into 2-dimensional histograms by Fourier
re-binning, and the images were reconstructed using a
two-dimensional ordered subset expectation maximization (2DOSEM)
algorithm (16 subsets, 4 iterations) into a 128.times.128.times.159
(0.78.times.0.78.times.0.80 mm) matrix. The image data was
normalized to correct for non-uniformity of response of the PET,
dead-time count losses, positron branching ratio, and physical
decay to the time of injection but no attenuation, scatter, or
partial-volume averaging correction was applied. Activity
concentrations (percentage of dose per gram of tissue [% ID/g]) and
maximum intensity projections were determined by conversion of the
counting rates from the reconstructed images. All of the resulting
PET images were analyzed using ASIPro VM.TM. software.
Acute Biodistribution with .sup.64Cu-Labeled Tetrazine
Radioligands
[0169] Healthy female athymic nude mice (n=4 per radioligand) were
administered .sup.64Cu-Tz-PEG.sub.7-NOTA or .sup.64Cu-Tz-SarAr
(25-30 .mu.Ci in 200 .mu.L, 0.9% sterile saline) via intravenous
tail vein injection (t=0). Animals (n=4 per group) were euthanized
by CO.sub.2(g) asphyxiation at 1, 4, 12, and 24 h after injection.
After asphyxiation, tissues were removed, rinsed in water, dried in
air for 5 min, weighed, and counted in a gamma counter calibrated
for .sup.64Cu. Counts were converted into activity using a
calibration curve generated from known standards. Count data were
background- and decay-corrected to the time of injection, and the
percent injected dose per gram (% ID/g) for each tissue sample was
calculated by normalization to the total activity injected.
Ex Vivo Autoradiography, Immunohistochemistry, and Histology
[0170] Following PET imaging, tumors were excised and embedded in
optimal-cutting-temperature mounting medium (OCT, Sakura Finetek)
and frozen on dry ice. Series of 10 .mu.m frozen sections were then
cut. To determine radiotracer distribution, digital autoradiography
was performed by placing tissue sections in a film cassette against
a phosphor imaging plate (Fujifilm BAS-MS2325; Fuji Photo Film) for
an appropriate exposure period at -20.degree. C. Phosphor imaging
plates were read at a pixel resolution of 25 .mu.m with a Typhoon
7000 IP plate reader (GE Healthcare). After autoradiographic
exposure, the same frozen sections were then used for fluorescence
staining and microscopy. Immunofluorescence staining and imaging of
A33 was performed essentially as previously described by Oehler et
al. in ".sup.18F-fluromisonidazole PET imaging as a biomarker for
the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal
xenograft tumors. Journal of Nuclear Medicine 2011, 52 (3), 437-44.
Frozen sections were fixed in 4% paraformaldehyde, and subsequently
incubated with huA33 primary antibody (5 .mu.g/ml) overnight at
4.degree. C., followed by secondary detection using goat anti human
Alexa-568 for 1 h at room temperature (20 .mu.g/ml, Molecular
Probes). Whole mount fluorescence images were acquired at .times.40
magnification using a BX60 fluorescence microscope (Olympus
America, Inc.) equipped with a motorized stage (Prior Scientific
Instruments Ltd.) and CC12 camera (Olympus). Whole-tumor montage
images were obtained by acquiring multiple fields at .times.40
magnification, followed by alignment using MicroSuite Biologic
Suite (version 2.7; Olympus). Fluorescence and autoradiographic
images were registered using Adobe Photoshop (CS6).
Dosimetry
[0171] Mouse biodistribution data were expressed as normal-organ
mean standard uptake values (SUVs) versus time post-administration.
In first order, that SUVs were independent of body mass and thus
the same among species, the mean SUV in mouse organ i,
SUV.sub.Organ i|Mouse, was converted to the fraction of the
injected dose in each human organ I, FID.sub.Organ I|Human, using
the following formula:
FID Organ i | Human = SUV ran i | Mouse Mass of Human Organ i Mass
of Human Total Body ##EQU00001##
and the organ and total-body masses of the 70-kg Standard Man
anatomic model. These data (corrected for radioactive decay to the
time of injection) were then fit to a mono-exponential or
bi-exponential time-activity function, depending on the organ. The
cumulated activity, or residence time, in human organ i,
.mu.C.sub.i, in .mu.C.sub.i h/.mu.C.sub.i, was then calculated by
analytically integrating the time-activity function in organ i,
replacing the biological clearance constant,
(.lamda..sub.b.lamda..sub.j. for each component j of the fitted
exponential function with the corresponding effective clearance
constant,
(.lamda..sub.e.lamda..sub.j=(.lamda..sub.b.kappa..sub.j+.lamda..sub.p,
where .lamda..sub.p is the physical decay constant of the
radionuclide. The resulting organ residence times were entered into
the OLINDA computer program to yield the mean organ absorbed doses
and effective dose in rad/mCi and rem/mCi, respectively.
Statistical Analysis
[0172] Data were analyzed by the unpaired, two-tailed Student's
t-test. Differences at the 95% confidence level (P less than 0.05)
were considered to be statistically significant.
.sup.18F-Based of Tetrazine Radioligands for Pretargeted
Imaging
[0173] Described herein is the development of strategies for
pretargeted PET imaging of pancreatic cancer featuring a
tetrazine-bearing radioligand with an improved pharmacokinetic
profile compared to prior systems. A TCO-bearing immuno-conjugate
of the anti-CA19.9 antibody 5B1 and an Al[18.sup.F]-NOTA-labeled
tetrazine radioligand were harnessed for the visualization of
CA19.9-expressing BxPC3 pancreatic cancer xenografts.
Biodistribution and .sup.18F-PET imaging data clearly demonstrate
that this methodology effectively delineates tumor mass with
activity concentrations up to 6.4% ID/g at 4 h after injection of
the radioligand.
[0174] The development of a novel Tz/TCO-based pretargeting
strategy using an Al[.sup.18F]-NOTA-labeled tetrazine radioligand
is described herein. As described below, the 5B1 antibody, a
fully-human IgG that targets a promising biomarker for pancreatic
ductal adenocarcinoma: carbohydrate antigen 19.9 (CA19.9) was
selected. In order to functionalize the antibody with a reactive
bioorthogonal moiety, purified 5B1 was incubated with an activated
succinimidyl ester of TCO (TCO-NHS, 35 eq.) at room temperature for
1 h. The immunoconjugate was subsequently purified by
gel-filtration chromatography. The precursor to the radioligand,
Tz-PEG.sub.11-NOTA (FIG. 27, 1), was synthesized from three
commercially available building blocks: (i)
2,5-dioxo-1-pyrrolidinyl
5-[4-(1,2,4,5-tetrazin-3-yl)benzylamino]-5-oxopentanoate (Tz-NHS),
(ii) O-(2-aminoethyl)-O'-[2-(boc-amino)ethyl]decaethylene glycol
(NH.sub.2-PEG.sub.11-NHBoc), and (iii)
S-2-(4-isothiocyanatobenzyl)-1,4,7-triaza-cyclononane-1,4,7-triacetic
acid (p-SCN-Bn-NOTA). After the peptide coupling between Tz-NHS and
NH.sub.2-PEG.sub.11-NHBoc and the subsequent deprotection of the
terminal tert-butyloxycarbonyl protecting group, the resulting
Tz-PEG.sub.11-NH.sub.2 moiety was reacted with the bifunctional
p-SCN-Bn-NOTA chelator. Ultimately, the precursor was prepared in
very high purity (greater than 98%) and with an overall yield of
.about.15% (n=3).
[0175] The .sup.18F-labeled radioligand
Tz-PEG.sub.11-Al[.sup.18F]-NOTA ([.sup.18F]2 (FIG. 27, 2) was
obtained in 54-65% radiochemical yield [decay-corrected (d.c.) to
the start of synthesis] in high purity (greater than 96%) and had a
specific activity between 21.4-26.7 GBq/.mu.mol. The use of
metal-free solvents, the pH of the Al[.sup.18F]-NOTA complexation
reaction (pH=4), and the ratio of reaction solvents (at least 3:1
MeCN/H.sub.2O) all proved to be crucial factors in obtaining high
radiochemical yields. Aqueous [.sup.18F]fluoride (non-carrier
added) was obtained from the cyclotron and loaded onto a
preconditioned anion-exchange (QMA) cartridge. Before elution of
the [.sup.18F]fluoride using 0.4 M KHCO.sub.3-solution (0.2 mL),
the cartridge was washed with metal-free water (10-15 mL) to elute
metal ions present in the original target water. Metal-free glacial
acid (.about.15-20 .mu.L) was used to adjust the pH to
.about.3.5-4, followed by the addition of 2 mM AlCl.sub.3-solution
(25 .mu.L). The resulting mixture was incubated at room temperature
for the formation of the Al-.sup.18F complex. Precursor 1 (40 nmol
in 700 .mu.L MeCN) was then added to the solution of Al[.sup.18F],
and the resulting mixture was stirred at 90.degree. C. for 15 min.
Subsequently, the .sup.18F-labeled product was purified using a
SepPak C18-cartridge (Waters, Milford, Mass.) and eluted with a
small volume of ethanol (0.3-0.4 mL). The in vitro stability of
[.sup.18F]2 was assayed by incubation in phosphate buffered saline
(PBS, pH 7.4) or human serum at 37.degree. C., followed by analysis
via radio-HPLC. In PBS, negligible decomposition could be observed
after 4 h (92.+-.2.3% intact), and 79.+-.4.4% (n=4) of the
radioligand remained intact in human serum at the same time point.
Given the fast reaction kinetics of the IEDDA ligation as well as
the relatively short half-life of .sup.18F, the observed
degradation rate is not considered a detriment to the system, as
shown for other Tz/TCO approaches.
[0176] The bioorthogonal click reaction between [.sup.18F]2 and the
TCO moiety on the antibody was demonstrated by incubation of
equimolar amounts (1.33 nmol) of the purified radioligand with
5B1-TCO at room temperature. Analysis of the reaction via radio-TLC
(mobile phase: 90% MeCN in H.sub.2O) revealed a greater than 94%
yield for the reaction, with the .sup.18F-labeled click reaction
product situated at the origin, while the free radioligand can be
detected at the solvent front.
[0177] In vivo biodistribution data for
Tz-PEG.sub.11-Al[.sup.18F]-NOTA were first obtained in healthy mice
by injecting [.sup.18F]2 alone (1.8-2.0 MBq) via the tail vein. The
data showed accumulation and retention of the radiotracer in the
large intestines and feces with 0.32.+-.0.87 percent injected dose
per gram (% ID/g) at 1 h after injection to 1.73.+-.0.45 (% ID/g)
at 4 h. The uptake and retention of [.sup.18F]2 could also be
observed in the kidneys (2.12.+-.0.23% ID/g at 1 h to 1.17.+-.0.12%
ID/g at 4 h), indicating dual renal and fecal elimination pathways
for the radioligand. The amount of activity in the blood decreased
over time, from 1.94.+-.0.23% ID/g at 1 h to 0.78.+-.0.08% ID/g at
4 h after injection, while the uptake in all other healthy tissues
remained less than 1% ID/g. Notably, the activity concentrations in
the bone were particularly low (not exceeding 0.2% ID/g),
illustrating in vivo stability of the Al[.sup.18F]-NOTA complex. In
accompanying experiments, the blood half-life of the radioligand
was calculated to be 71.2 min.
[0178] In subsequent pretargeted biodistribution experiments, nude,
athymic mice bearing subcutaneous CA19.9-expressing BxPC3
xenografts were injected with 5B1-TCO (1.33 nmol) 72 h prior to the
administration of [.sup.18F]2 (1.33 nmol, 1.8-2.0 MBq). The data
revealed increasing tumoral uptake over the course of the study
(3.0.+-.0.32% ID/g at 30 min, 3.52.+-.0.67% ID/g at 1 h,
4.81.+-.1.23% ID/g at 2 h to 5.6.+-.0.85% ID/g at 4 h), with the
amount of radioactivity in the blood decreasing in kind, from
6.13.+-.0.86% ID/g at 30 min to 1.75.+-.0.22% ID/g at 4 h. In
accordance to the biodistribution data obtained from healthy mice,
the uptake in other tissue remained generally low (less than or
equal to 2% ID/g), with the highest uptake and retention in the
clearance organs: the intestines and kidneys (FIG. 28).
[0179] The clearance of radioactivity from the blood pool was
generally in line with the calculated blood half-life of the
radiotracer, and the steady uptake of radioactivity at the tumor
suggested that the radioligand is primarily clicking with 5B1-TCO
at the tumor site rather than clicking in the blood pool followed
by accumulation at the tumor.
[0180] Small animal PET imaging experiments were conducted in a
similar fashion, with the only difference in the amount of
radioactivity injected (18-20 MBq, 1.33 nmol of [.sup.18F]2,
equimolar to 5B1-TCO). The PET images as shown in FIG. 29 confirm
the data obtained in the biodistribution study: the signal in the
tumor increases with time, while the activity concentrations in the
blood and intestines concomitantly decrease. This results in the
clear delineation of the tumor from background tissue, with the
tumor-to-background activity ratios improving over the course of
the experiment. The tumoral uptake of [.sup.18F]2 is immediately
evident 1 h after injection; however, the signal grows to 6.4% ID/g
at 4 h after the administration of the radioligand. While the
tumor-to-background activity concentration ratios improve over
time, radioactivity had not cleared the intestines at 4 h
post-injection. Therefore, second generation tetrazine-bearing
radioligands can be developed in an effort to determine whether
structural alterations can increase the fraction of the radioligand
that is excreted via the renal system, and thus create higher
tumor-to-background ratios at earlier time points. Finally, using
the biodistribution data, a dosimetric analysis of the pretargeting
strategy was performed that confirms that pretargeted PET imaging
with Tz-PEG.sub.11-Al.sup.18F-NOTA and 5B1-TCO confers a
significant dosimetric advantage over the use of antibodies
directly labeled with long-lived radioisotopes (e.g., in the case
.sup.89Zr-DFO-5B1). The effective dose of the presented
.sup.18F-based pretargeting system (0.03 rem/mCi) is more than 60
times lower than directly labeled .sup.89Zr-DFO-5B1 (2.02
rem/mCi).
[0181] Thus, the .sup.18F-based pretargeted PET imaging system
described herein shows highly promising biodistribution results and
produced tumor activity concentrations of up to 6.4% ID/g at 4 h
post-injection. Small-animal PET imaging experiments revealed that
this methodology clearly delineates CA19.9-expressing tissues, with
especially enticing tumor-to-background activity ratios 2 h and 4 h
after injection of the radiotracer.
[0182] All starting materials except the NOTA-Bn-p-NSC that was
purchased from Macrocyclics were purchased from Sigma-Aldrich
(synthetic-grade) and were used without further purification. All
solvents used for HPLC analysis and purification within this
project were purchased from Fisher Scientific (HPLC grade).
Metal-free DMSO (greater than or equal to 99.99995%) and MeCN
(greater than or equal to 99.999%) were purchased from
Sigma-Aldrich. Water (greater than 18.2 M.OMEGA. cm-1 at 25.degree.
C.) was obtained from an Alpha-Q Ultrapure water system from
Millipore (Bedford, Mass.).
[0183] Proton (.sup.1H) NMR spectra were measured on a BrukerAvance
Ultra Shield (500 MHz) spectrometer at ambient temperature. Data
were recorded as follows: chemical shift in ppm from internal
reference tetramethylsilane on the scale, multiplicity (s=singlet;
d=doublet; t=triplet; m=multiplet), coupling constant (Hz),
integration, and assignment. Carbon (.sup.13C) NMR spectra were
measured on a BrukerAvance Ultra Shield (125 MHz) spectrometer at
ambient temperature. Chemical shifts were recorded in ppm from the
solvent resonance employed as the internal standard
(deuterochloroform at 77.00 ppm).
[0184] Non-carrier-added (n.c.a.) .sup.18F-fluoride was obtained
via the .sup.18O(p,n).sup.18F nuclear reaction of 11-MeV protons in
an EBCO TR-19/9 cyclotron using enriched .sup.18O-water. QMA light
ion-exchange cartridges and C-18 light Sep-Pak.RTM. cartridges were
obtained from Waters (Milford, Mass.). C18 cartridges were
equilibrated using absolute ethanol (10 mL) followed by deionized
water (5 mL). QMA cartridges used a Chromafix 30-PS-HCO3-resin for
ion-exchange and were equilibrated using KHCO3-solution (0.4 M, 5
mL) followed by deionized water (10 mL). High performance liquid
chromatography (HPLC) purification and analysis was performed on a
Shimadzu UFLC HPLC system equipped with a DGU-20A degasser, a
SPD-M20A UV detector, a RF-20Axs fluorescence detector, a LC-20AB
pump system, and a CBM-20A communication BUS module. A LabLogic
Scan-RAM radio-TLC/HPLC-detector was used for purifications while a
PosiRAM Model 4 was used for analysis. HPLC solvents (Buffer A:
0.1% TFA in water, Buffer B: 0.1% TFA in MeCN) were filtered before
use. HPLC analysis of radioactive and non-radioactive compounds was
performed on a reversed phase Atlantis T3 column (C18, 5 .mu.m, 4.6
mm.times.250 mm). Preparative HPLC purification was carried out on
a reversed phase Waters XTerra Prep C18 OBD (C18, 10 .mu.m, 19
mm.times.250 mm). For radioactive thin-layer chromatography (TLC)
analysis throughout this work, Merck precoated TLC plates (C18,
reversed-phase) were used. Radio-TLC was performed using a Canberra
190 5 Experimental Part UNISPEC iScan (Meriden, Conn., USA)
instrument. Radioactivity was determined using a calibrated ion
chamber (Capintec CRC-15R).
[0185] Electrospray ionization mass spectrometry (ESI-MS) spectra
were recorded with a Shimadzu LC-2020 with electrospray ionization
SQ detector. High-resolution mass spectrometry (ESI-HRMS) was
carried out on a Micromass LCT Premier XE using a reversed phase
Waters XBridge column (C18, 5 .mu.m, 4.6 mm.times.50 mm).
Syntheses
tert-butyl-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-3,7-dioxo-11,14,17,20,23,2-
6,29,32,35,38,41-undecaoxa-2,8-diazatritetracontan-43-yl)carbamate
(Tz-PEG.sub.11-NHBoc)
##STR00006##
[0187] 2,5-Dioxo-1-pyrrolidinyl
5-[4-(1,2,4,5-tetrazin-3-yl)benzylamino]-5-oxopentanoate (Tz-NHS,
10 mg, 0.025 mmol) was dissolved in anhydrous dimethylsulfoxide
(DMSO, 0.5 mL) before
O-(2-Aminoethyl)-O'-[2-(Boc-amino)ethyl]decaethylene glycol (24.2
mg, 0.0375 mmol) and TEA (0.0057 mL, 0.0375 mmol) were added, The
reaction mixture was stirred at room temperature for 45 min After
completion of the reaction (monitored by HPLC, 5% MeCN/H to 95%
MeCN over 20 min, R.sub.t=14.2 min, 1 mL/min) the product was
purified using preparative HPLC (5% MeCN/H to 95% MeCN over 20 min
R.sub.t=14.5 min, 8 mL/min) with purity greater than 95%. The
product was furnished as a pink solid (18.2 mg, 96%). .sup.1H NMR
(500 MHz, DMSO-d.sub.6) .delta. 10.65 (s, 1H), 8.77 (t, J=5.4 Hz,
1H), 8.65-8.57 (m, 2H), 8.16-8.12 (m, 2H), 6.77-6.73 (m, 1H),
3.62-3.42 (m, 46H), 3.38 (t, J=6.1 Hz, 3H), 3.07 (q, J=5.8 Hz, 2H),
1.38 (s, 9H); MS (ESI) m/z 929.3 [M+H].sup.+, HRMS (ESI) calcd. for
C.sub.43H.sub.73N.sub.7NaO.sub.15 [=M+Na].sup.+ m/z 950.5062. found
950.5034.
N.sup.1-(4-(1,2,4,5-tetrazin-3-yl)benzyl)-N.sup.5-(35-amino-3,6,9,12,15,18-
,21,24,27,30,33-undecaoxa-pentatriacontyl)glutaramide
(Tz-PEG.sub.11-NH.sub.2)
##STR00007##
[0189] Tz-PEG.sub.11-NHBoc (16.3 mg, 0.0216 mmol) was dissolved in
dichloromethane (DCM, 0.5 mL) before TFA (0.1 mL) was added drop
wise. The resulting solution was stirred at room temperature for 30
min. The solvent was removed under reduced pressure before the
deprotected product was purified via preparative HPLC (5% MeCN/H to
95% MeCN over 20 min, R.sub.t=11.6 min, 8 mL/min) with purity
greater than 97%. The product was furnished as a pink solid (14.4
mg, 92%), .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 10.59 (s,
1H), 8.74 (t, J=5.2 Hz, 1H), 8.61-8.55 (m, 2H), 8.12-8.09 (m, 2H),
6.79-6.74 (m, 1H), 3.68-3.36 (m, 46H), 3.34 (t, J=6.1 Hz, 3H), 3.10
(q, J=5.8 Hz, 2H); MS (ESI) m/z 829.2 [M+H].sup.+, HRMS (ESI) calcd
for C.sub.38H.sub.66N.sub.7O.sub.13 [=M+H].sup.+ m/z 828.4719.
found 828.4742.
2,2',2''-(3-(4-(3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-3,7-dioxo-11,14,17,-
20,23,26,29,32,35,38,-41-undecaoxa-2,8-diazatritetracontan-43-yl)thioureid-
o)benzyl)-1,4,7-triazonane-2,5,8-triyl)triacetic acid
(Tz-PEG.sub.11-NOTA)
##STR00008##
[0191] Tz-PEG.sub.11-NH.sub.2 (13.5 mg, 0.0216 mmol) was dissolved
in DMSO (0.5 mL) before NOTA-Bn-NCS (20.2 mg, 0.036 mmol) and TEA
(0.0057 mL, 0.0375 mmol) were added. The reaction mixture was
stirred at room temperature for 45 min. After completion of the
reaction (monitored by HPLC, 5% MeCN/H to 95% MeCN over 20 min,
R.sub.t=13.2 min, 1 ml/min) the product was purified using
preparative HPLC (5% MeCN/H.sub.2O to 95% MeCN over 30 min,
R.sub.t=13.6 min., 8 mL/min) with purity greater than 97%. The
product was furnished as a pink solid (20.2 mg, 73%). .sup.1H NMR
(500 MHz, DMSO-d.sub.6) .delta. 10.59 (s, 1H), 8.47 (d, J=7.3 Hz,
3H), 7.87 (t, J=5.2 Hz, 3H), 7.55 (d, J=7.6 Hz, 3H), 7.43 (d, J=8.1
Hz, 3H), 7.20 (d, J=7.7 Hz, 2H), 4.41 (d, J=5.8 Hz, 3H), 4.00 (d,
J=17.5 Hz, 2H), 3.82 (d, J=17.9 Hz, 4H), 3.51 (s, 53H), 2.20 (t,
J=7.4 Hz, 3H), 2.12 (t, J=7.5 Hz, 5H), 1.78 (dt, J=14.4, 7.2 Hz,
4H); MS (ESI) m/z 829.2 [M+H].sup.+1, HRMS (ESI) calcd for
C.sub.43H.sub.73N.sub.7O.sub.15 [=M-H].sup.- m/z 1276.6135. found
1276.6179.
Tz-PEG.sub.11-Al[.sup.18F]-NOTA.
##STR00009##
[0192] The [.sup.18F]fluoride received from the cyclotron was
trapped on a preconditioned QMA cartridge. The cartridge was
subsequently washed with metal-free water (10-15 mL) before the
[.sup.18F]fluoride (0.9-1.1 GBq) was eluted using 0.4 M
KHCO3-solution (0.2 mL) into a V-vial. The pH of the solution was
adjusted to .about.4 using glacial acetic acid (15-20 .mu.L)
followed by the addition of 2 mM AlCl.sub.3-solution (25 .mu.L).
The resulting solution was incubated at room temperature for 20 min
to form the Al-.sup.18F complex. The precursor Tz-PEG.sub.11-NOTA
dissolved in MeCN (700 .mu.L) was then added to the aqueous
solution containing the Al-.sup.18F complex and the resulting
mixture stirred at 90.degree. C. for 15 min. After the given period
of time the reaction vial was cooled using dry ice before the
reaction mixture was diluted with water (20 mL). The obtained
aqueous solution containing the labeled product was flushed through
a preconditioned C18 cartridge followed by an additional 10 mL of
water to remove left over [.sup.18F]fluoride from the cartridge.
The product [.sup.18F]2 was subsequently eluted with EtOH (0.3-05
mL) and analyzed for purity using radio-HPLC (5% MeCN/H.sub.2O to
95% MeCN over 20 min, Rt=11.5 min, 1 ml/min). Prior to each animal
experiment the EtOH was removed under reduced pressure and the
tracer was reconstituted in 0.9% saline for injections.
In Vitro Stability Testing
[0193] Table 24 shows results obtained from the in vitro stability
study of the radioligand [.sup.18F]2. The values are given as
percent intact tracer after incubation.
TABLE-US-00025 TABLE 24 Conditions Time PBS (pH = 7.4) [%] Human
Serum [%] 30 min 98.5 .+-. 1.0 95.5 .+-. 1.5 1 h 96.5 .+-. 2.5 91.5
.+-. 2 2 h 93 .+-. 1.0 85 .+-. 4.5 4 h 91.5 .+-. 1.5 74.5 .+-.
5.5
[0194] The radioligand was incubated with agitation (600 rpm) at
37.degree. C. in 500 .mu.L of either PBS or human serum. At the
appropriate time points, 100 .mu.L of the solution was transferred
into a 1.7 mL centrifuge tube. In case of PBS, the aliquot was
directly injected into the HPLC. For the serum samples, 100 .mu.L
of MeCN was added to the previously transferred 100 .mu.L serum
solution and the resulting solution was vortexed and centrifuged
(13,000 rpm) for 5 min. The clear supernatant was removed, moved to
a new centrifuge tube followed by additional centrifugation at
13,000 rpm for 5 min. The resulting clear supernatant was then used
for HPLC analysis (FIGS. 30A and 30B). The residual protein was
checked for radioactivity, and only minimal residual radioactivity
could be detected (e.g., less than 2%). The fraction of intact
radioligand was calculated by dividing the peak area corresponding
to the tracer by the integral of the entire HPLC run. The observed
decomposition of the radioligand in human serum is likely related
to the presence of nucleophilic sulfhydryl and amino groups in the
serum that could, even at neutral pH, have a measurable negative
effect on the stability of the tetrazine radioligand.
Click Reaction of Tz-PEG.sub.11-Al[.sup.18F]-NOTA with TCO-Modified
5B1
[0195] The click reaction between the radioligand and the TCO
moiety of the TCO-modified 5B1 antibody was demonstrated by
incubating an equimolar amount (1.33 nmol) of the purified tracer
[.sup.18F]2 with 5B1-TCO in PBS (pH=7.4) at room temperature for 15
min. A small aliquot of the reaction mixture was spotted onto a C18
TLC plate. TLC was performed using 90% MeCN in H.sub.2O as mobile
phase and analyzed by radio-TLC. The free radioligand in a control
run could be detected at the solvent front (FIG. 31A) whereas the
.sup.18F-labeled click reaction product (FIG. 31B) was situated at
the origin showing that the click reaction was completed after 15
min.
Cell Culture
[0196] BxPC3 cells were purchased from ATCC (Manassas, Va.) and
grown in RPMI modified to contain 4.5 g/L glucose and 1.5 g/L
sodium bicarbonate and supplemented with 10% (v/v) fetal calf
serum, 10 mM HEPES, 1 mM sodium pyruvate, 2 mM L-glutamine, 10 cc/L
non-essential amino acids, 100 IU penicillin and 100 ug
streptomycin.
In Vivo Models
[0197] All animal experiments within this study were performed in
accordance with protocols approved by the Institutional Animal Care
and Use Committee of MSKCC and followed National Institutes of
Health guidelines for animal welfare. Female athymic nude
CrTac:NCr-Foxn1.sup.nu mice at age 6-8 weeks were purchased from
Charles River Laboratories. For subcutaneous injections, mice were
anesthetized with 2% isoflurane (Baxter Healthcare) (2 L/min
medical air) before BxPC3 cells were implanted subcutaneously
(5.times.10.sup.6 cells in 150 .mu.L 1:1 growth media/Matrigel.RTM.
(BD Biosciences, San Jose, Calif.) in the right shoulder and
allowed to grow for approximately 3-4 weeks until the tumors
reached 5-10 mm in size. For all intravenous injections, mice were
gently warmed with a heat lamp and placed on a restrainer. The
tails were sterilized with alcohol pads, and injection took place
via the lateral tail vein.
Biodistribution in Healthy Nude Mice
[0198] The radioligand Tz-PEG.sub.11-Al.sup.18F-NOTA was injected
into healthy mice via the tail vein (FIG. 32). The organs were
harvested at the appropriate time points after the animals were
euthanized by CO.sub.2 asphyxiation. The collected organs were
weighed and counted in a WIZARD.sup.2 automatic .gamma.-counter
(PerkinElmer, Boston, Mass.). Generally, radioactivity was taken
and retained in the intestines and kidneys. Blood pool clearance
occurred slower than anticipated for small molecule radiotracer,
however, the clearance pattern was in line with the determined
blood half-life of 74.4 minutes.
[0199] The identical method was used in case of the pretargeted
biodistribution experiments.
Blood Half-Life Determination of Tz-PEG.sub.11-Al[.sup.18
F]-NOTA
[0200] The tracer Tz-PEG.sub.11-Al[.sup.18F]-NOTA ([.sup.18F]2) was
injected into healthy nude mice via the tail vein. Blood was
collected through the saphenous vein at the appropriate time points
(FIG. 33). The collection tubes were weighed before and after blood
collection and measured for radioactivity in order to calculate the
percent injected dose per gram values for each time point and
sample (n=4 for each time point). The half-life was subsequently
calculated to 74.4 minutes.
Dosimetry
[0201] The pretargeted biodistribution data obtained from the
utilized mouse model were first expressed as normal-organ mean
standard uptake values (SUVs) versus time post-injection. It was
assumed that SUVs are, in first order, independent of body mass and
hence the same among species. The mean SUV in mouse organ in every
mouse organ was then used to calculate the mean SUV of the same
organs in a human using the organ and total-body masses of the 70
kg Standard Man anatomic model. These data were then corrected for
radioactive decay to the time of injection and subsequently fitted
to a mono-exponential or bi-exponential time-activity function,
depending on the organ. This information was used to determine the
organ residence times which were then entered into the OLINDA
computer program to yield the mean organ absorbed doses and
effective dose in rad/mCi and rem/mCi, respectively. The data
obtained from the herein presented .sup.18F-based pretargeting
system were compared to the pretargeting system previously
described by Viola-Villegas et al. using .sup.89Zr-labeled 5B1 for
pretargeting CA19.9 (Table 25).
[0202] Table 25 shows mean organ absorbed doses and effective dose
calculated for the herein described pretargeting approach given in
rad/mCi and rem/mCi, respectively, compared to the pretargeting
system previously by N. T. Viola-Villegas, S. L. Rice, S. Carlin,
X. Wu, M. J. Evans, K. K. Sevak, M. Drobjnak, G. Ragupathi, R.
Sawada, W. W. Scholz, P. O. Livingston, J. S. Lewis, J. Nucl. Med,
2013, 54, 1876-1882, using .sup.89Zr-labeled 5B1 for pretargeting
CA19.9.
TABLE-US-00026 TABLE 25 Target Organ .sup.18F pretargeting
.sup.89Zr-DFO-5B1.sup.# Adrenals 0.0288 2.22 Brain 0.0256 1.7
Breasts 0.0214 1.36 Gallbladder Wall 0.0297 2.13 LLI Wall 0.0487
2.22 Small Intestine 0.0356 2.1 Stomach Wall 0.0401 2.2 ULI Wall
0.0424 1.98 Heart Wall 0.0279 2.15 Kidneys 0.113 2.86 Liver 0.0223
2.52 Lungs 0.0181 2.52 Muscle 0.0138 1.59 Ovaries 0.0299 1.98
Pancreas 0.0327 2.26 Red Marrow 0.0227 4.01 Osteogenic Cells 0.0366
5.08 Skin 0.018 1.17 Spleen 0.0997 3.7 Testes 0.0233 1.51 Thymus
0.0234 1.71 Thyroid 0.0235 1.69 Urinary Bladder Wall 0.0286 1.86
Uterus 0.0306 1.99 Total Body 0.0235 1.86 Effective dose 0.0302
2.02
Exemplary Tetrazine Precursors Available for Radiolabeling with
.sup.18F
[0203] Below are listed examples of available tetrazine-based
precursor molecules that can be used for radiolabeling with
.sup.18F using the Al[.sup.18F]-NOTA methodology.
Tetrazine Structures Connected to NOTA-Chelators Via
PEG-Linkers:
##STR00010## ##STR00011## ##STR00012## ##STR00013##
##STR00014##
[0204] Tetrazine Structures Connected to NOTA/NODA-Chelators Via
(Poly)-L-Lysine-Linkers:
##STR00015## ##STR00016##
* * * * *